STOCK TITAN

BioLargo revenue falls to $3.45M; going-concern warning

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

BioLargo, Inc. (BLGO) reported nine-month revenue of $3.452 million, down from $7.148 million a year earlier, while net loss was $11.229 million versus $11.047 million. Product revenue fell to $1.525 million from $5.584 million; service revenue increased to $1.927 million from $1.564 million. Operating cash use was $8.182 million, and cash stood at $1.533 million as of September 30, 2026.

The company reported a $2.391 million working-capital deficit and substantial doubt about its ability to continue as a going concern, citing recurring losses, negative cash flow and uncertainty about future operating revenue and gross profit. It said further investment capital is expected to be needed and management may curtail operations if additional cash is unavailable. Financing provided $6.075 million in net cash, 77% through subsidiary financings.

Under a purchase agreement with Clearthink Capital Partners, LLC, BioLargo sold 10.35 million shares for $1.103 million through September 30, 2026; purchases may be directed through May 1, 2029, subject to limits. BioLargo shares outstanding were 338,443,806 as of November 12, 2026.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

1 major · 3 points

How the balance works

Positive

  • None.

Negative

  • Major pointGoing-concern warning cites a $2.391 million working-capital deficit.
  • Moderate pointNine-month revenue fell to $3.452 million from $7.148 million in 2025.
  • Moderate pointOperating cash use increased to $8.182 million from $6.707 million in 2025.

Filing Explained

BioLargo issued 2,512,444 shares for services in the quarter and guaranteed payment of $675,000 in Clyra notes, adding dilution and parent-level exposure.

Form 10-Q is the unaudited quarterly report; BioLargo reports that it guaranteed payment of $675,000 in notes issued by Clyra, putting a parent-company guarantee behind the subsidiary’s borrowing.

The notes carry 15% annual interest and mature July 31, 2029; lenders also received warrants to buy 90,001 Clyra shares, not BioLargo common shares.

BioLargo also issued 2,512,444 common shares for services in the quarter, including 1,807,444 shares in place of $154,000 owed to two officers; these issued shares increase the share count and reduce existing holders’ percentage ownership, absent offsetting changes.

As of September 30, 2026, the filing lists 84,497,408 BioLargo options and 25,666,478 warrants outstanding; these are potential common-share issuances, not shares already issued.

Nine-month revenue $3.452 million Nine months ended September 30, 2026; $7.148 million in the same period of 2025
Net loss $11.229 million Nine months ended September 30, 2026; $11.047 million in the same period of 2025
Net cash used in operating activities $8.182 million Nine months ended September 30, 2026; $6.707 million in the same period of 2025
Cash and cash equivalents $1.533 million As of September 30, 2026
Current liabilities $5.936 million As of September 30, 2026
Working-capital deficit $2.391 million As of September 30, 2026
Net cash provided by financing activities $6.075 million Nine months ended September 30, 2026; 77% was received through subsidiary financings
Clearthink share-sale proceeds $1.103 million Gross and net proceeds from 10.35 million shares sold from April 15 through September 30, 2026
going concern financial
"substantial doubt about our ability to continue as a going concern"
Going concern is the accounting assumption that a company will keep operating and meeting its obligations for the foreseeable future. The phrase matters most when a company or its auditors disclose substantial doubt about it, a formal warning that the business may not have enough resources to continue without raising money, restructuring, or selling assets. That language in a filing or press release signals elevated financial risk.
working capital deficit financial
"working capital deficit of $2,391,000"
A working capital deficit occurs when a company's short-term obligations—like bills, supplier payments and near-term debt—are larger than its readily available short-term resources such as cash, money expected from customers, and inventory that can be sold. Like a household whose monthly bills exceed its checking account, it signals potential difficulty paying immediate expenses, which matters to investors because it raises the chance the company will need outside financing or cut operations, affecting risk and value.
contract liability financial
"a corresponding contract liability"
A contract liability is a legally binding obligation a company has under a contract to deliver goods, services, or a refund in the future in exchange for money or another benefit already received. Investors care because these obligations represent future cash outflows or performance risks—like an IOU on a household chore list—that can reduce available cash, affect earnings reliability, and change how risky or valuable a company’s financial position looks.
noncontrolling interest financial
"Noncontrolling interest on the Company’s condensed consolidated balance sheets"
The portion of a business owned by investors other than the controlling owner when one company has control of another; it represents outside shareholders’ share of the subsidiary’s assets and profits. For investors, it matters because those outside claims reduce the amount of profit and net assets attributable to the parent owner — similar to saying part of a pizza belongs to someone else — and thus affects earnings, book value and valuation.
beneficial conversion feature financial
"discounted by the beneficial conversion feature"
performance obligation financial
"The only performance obligation is to create and ship the product"
A performance obligation is a specific promise in a contract to deliver a good or provide a service to a customer, and it is the unit companies use to decide when and how much revenue to record. Think of it like checklist items in a service agreement: each item completed can trigger part of the payment to be recognized as revenue. Investors care because how obligations are identified and satisfied changes the timing and amount of reported revenue and profits, affecting comparisons and valuation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What was BLGO's revenue for the first nine months of 2026?

BioLargo reported $3.452 million in revenue for the nine months ended September 30, 2026, compared with $7.148 million in the same period of 2025. Product revenue was $1.525 million and service revenue was $1.927 million in 2026.

Why does BLGO report substantial doubt about continuing as a going concern?

BioLargo cited recurring losses, negative cash flow and uncertainty about future operating revenue and gross profits. It said it is unknown whether gross profits in the next 12 months will be sufficient to fund operating costs, expects to need further investment capital, and may curtail portions of its operations if it cannot raise additional cash.

How much can BioLargo sell under its Clearthink agreement, and what are the purchase limits?

Clearthink committed to purchase up to $10.0 million of BioLargo common stock. From April 15, 2026 through May 1, 2029, unless BioLargo is in default, BioLargo may direct purchases on selected trading days, each up to the lesser of $500,000 or 300% of the daily average shares-traded value for the preceding eight trading days, with a minimum of $25,000. Purchase notices must be at least five business days apart unless both parties agree otherwise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000880242 BIOLARGO, INC. false --12-31 Q3 2026 34 139 441 56 0.00067 0.00067 50,000,000 50,000,000 0 0 0 0 0.00067 0.00067 550,000,000 550,000,000 334,843,806 317,377,777 15 15 15 15 5 1,378,141 0 3 5,000 6 18 0 30 6 5 0 0 4 235,000 1 10 1 10 2 1 5 0 15 11,878,545 11,375,860 746,418 330,000 5,305,156 165,765 3 5 2 82,000 10 5 30 9,880,361 9,605,826 7 5 false false false false Aggregate intrinsic value based on closing common stock price of $0.16 at March 31, 2026. Aggregate intrinsic value based on closing common stock price of $0.16 at March 31, 2026 00008802422026-01-012026-09-30 xbrli:shares 00008802422026-11-12 thunderdome:item iso4217:USD 00008802422026-09-30 00008802422025-12-31 0000880242blgo:PartiallyOwnedSubsidiaryMember2026-09-30 0000880242blgo:PartiallyOwnedSubsidiaryMember2025-12-31 0000880242blgo:EntitiesExcludingPartiallyOwnedSubsidiaryMember2026-09-30 0000880242blgo:EntitiesExcludingPartiallyOwnedSubsidiaryMember2025-12-31 0000880242blgo:DebtObligationsMember2026-09-30 0000880242blgo:DebtObligationsMember2025-12-31 iso4217:USDxbrli:shares 0000880242us-gaap:ProductMember2026-07-012026-09-30 0000880242us-gaap:ProductMember2025-07-012025-09-30 0000880242us-gaap:ProductMember2026-01-012026-09-30 0000880242us-gaap:ProductMember2025-01-012025-09-30 0000880242us-gaap:ServiceMember2026-07-012026-09-30 0000880242us-gaap:ServiceMember2025-07-012025-09-30 0000880242us-gaap:ServiceMember2026-01-012026-09-30 0000880242us-gaap:ServiceMember2025-01-012025-09-30 00008802422026-07-012026-09-30 00008802422025-07-012025-09-30 00008802422025-01-012025-09-30 0000880242us-gaap:CommonStockMember2025-12-31 0000880242us-gaap:AdditionalPaidInCapitalMember2025-12-31 0000880242us-gaap:RetainedEarningsMember2025-12-31 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-12-31 0000880242us-gaap:NoncontrollingInterestMember2025-12-31 00008802422026-01-012026-03-31 0000880242us-gaap:CommonStockMember2026-01-012026-03-31 0000880242us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31 0000880242us-gaap:RetainedEarningsMember2026-01-012026-03-31 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31 0000880242us-gaap:NoncontrollingInterestMember2026-01-012026-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:CommonStockMember2026-01-012026-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:RetainedEarningsMember2026-01-012026-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:NoncontrollingInterestMember2026-01-012026-03-31 0000880242blgo:ClyraMedicalTechnologiesMember2026-01-012026-03-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:CommonStockMember2026-01-012026-03-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:RetainedEarningsMember2026-01-012026-03-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-01-012026-03-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:NoncontrollingInterestMember2026-01-012026-03-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-01-012026-03-31 0000880242us-gaap:CommonStockMember2026-03-31 0000880242us-gaap:AdditionalPaidInCapitalMember2026-03-31 0000880242us-gaap:RetainedEarningsMember2026-03-31 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-03-31 0000880242us-gaap:NoncontrollingInterestMember2026-03-31 00008802422026-03-31 0000880242us-gaap:CommonStockMember2026-04-012026-06-30 0000880242us-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-30 0000880242us-gaap:RetainedEarningsMember2026-04-012026-06-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-30 0000880242us-gaap:NoncontrollingInterestMember2026-04-012026-06-30 00008802422026-04-012026-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:CommonStockMember2026-04-012026-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:RetainedEarningsMember2026-04-012026-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:NoncontrollingInterestMember2026-04-012026-06-30 0000880242blgo:ClyraMedicalTechnologiesMember2026-04-012026-06-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:CommonStockMember2026-04-012026-06-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:RetainedEarningsMember2026-04-012026-06-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:NoncontrollingInterestMember2026-04-012026-06-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-04-012026-06-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:CommonStockMember2026-04-012026-06-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:AdditionalPaidInCapitalMember2026-04-012026-06-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:RetainedEarningsMember2026-04-012026-06-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-04-012026-06-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:NoncontrollingInterestMember2026-04-012026-06-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMember2026-04-012026-06-30 0000880242us-gaap:CommonStockMember2026-06-30 0000880242us-gaap:AdditionalPaidInCapitalMember2026-06-30 0000880242us-gaap:RetainedEarningsMember2026-06-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-06-30 0000880242us-gaap:NoncontrollingInterestMember2026-06-30 00008802422026-06-30 0000880242us-gaap:CommonStockMember2026-07-012026-09-30 0000880242us-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0000880242us-gaap:RetainedEarningsMember2026-07-012026-09-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-30 0000880242us-gaap:NoncontrollingInterestMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:CommonStockMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:RetainedEarningsMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:NoncontrollingInterestMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:CommonStockMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:AdditionalPaidInCapitalMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:RetainedEarningsMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMemberus-gaap:NoncontrollingInterestMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMember2026-07-012026-09-30 0000880242us-gaap:CommonStockMember2026-09-30 0000880242us-gaap:AdditionalPaidInCapitalMember2026-09-30 0000880242us-gaap:RetainedEarningsMember2026-09-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2026-09-30 0000880242us-gaap:NoncontrollingInterestMember2026-09-30 0000880242us-gaap:CommonStockMember2024-12-31 0000880242us-gaap:AdditionalPaidInCapitalMember2024-12-31 0000880242us-gaap:RetainedEarningsMember2024-12-31 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-31 0000880242us-gaap:NoncontrollingInterestMember2024-12-31 00008802422024-12-31 00008802422025-01-012025-03-31 0000880242us-gaap:CommonStockMember2025-01-012025-03-31 0000880242us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0000880242us-gaap:RetainedEarningsMember2025-01-012025-03-31 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31 0000880242us-gaap:NoncontrollingInterestMember2025-01-012025-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:CommonStockMember2025-01-012025-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:RetainedEarningsMember2025-01-012025-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-01-012025-03-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:NoncontrollingInterestMember2025-01-012025-03-31 0000880242blgo:ClyraMedicalTechnologiesMember2025-01-012025-03-31 0000880242us-gaap:CommonStockMember2025-03-31 0000880242us-gaap:AdditionalPaidInCapitalMember2025-03-31 0000880242us-gaap:RetainedEarningsMember2025-03-31 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-03-31 0000880242us-gaap:NoncontrollingInterestMember2025-03-31 00008802422025-03-31 00008802422025-04-012025-06-30 0000880242us-gaap:CommonStockMember2025-04-012025-06-30 0000880242us-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-30 0000880242us-gaap:RetainedEarningsMember2025-04-012025-06-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-30 0000880242us-gaap:NoncontrollingInterestMember2025-04-012025-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:CommonStockMember2025-04-012025-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AdditionalPaidInCapitalMember2025-04-012025-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:RetainedEarningsMember2025-04-012025-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-04-012025-06-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:NoncontrollingInterestMember2025-04-012025-06-30 0000880242blgo:ClyraMedicalTechnologiesMember2025-04-012025-06-30 0000880242us-gaap:CommonStockMember2025-06-30 0000880242us-gaap:AdditionalPaidInCapitalMember2025-06-30 0000880242us-gaap:RetainedEarningsMember2025-06-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-06-30 0000880242us-gaap:NoncontrollingInterestMember2025-06-30 00008802422025-06-30 0000880242us-gaap:CommonStockMember2025-07-012025-09-30 0000880242us-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0000880242us-gaap:RetainedEarningsMember2025-07-012025-09-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-30 0000880242us-gaap:NoncontrollingInterestMember2025-07-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:CommonStockMember2025-07-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:RetainedEarningsMember2025-07-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMemberus-gaap:NoncontrollingInterestMember2025-07-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:CommonStockMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:RetainedEarningsMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:NoncontrollingInterestMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMemberus-gaap:CommonStockMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMemberus-gaap:RetainedEarningsMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMemberus-gaap:NoncontrollingInterestMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:RetainedEarningsMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:AccumulatedOtherComprehensiveIncomeMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesAPreferredStockMemberus-gaap:NoncontrollingInterestMember2025-07-012025-09-30 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesAPreferredStockMember2025-07-012025-09-30 0000880242us-gaap:CommonStockMember2025-09-30 0000880242us-gaap:AdditionalPaidInCapitalMember2025-09-30 0000880242us-gaap:RetainedEarningsMember2025-09-30 0000880242us-gaap:AccumulatedOtherComprehensiveIncomeMember2025-09-30 0000880242us-gaap:NoncontrollingInterestMember2025-09-30 00008802422025-09-30 0000880242blgo:EntitiesExcludingPartiallyOwnedSubsidiaryMember2026-01-012026-09-30 0000880242blgo:EntitiesExcludingPartiallyOwnedSubsidiaryMember2025-01-012025-09-30 0000880242blgo:PartiallyOwnedSubsidiaryMember2026-01-012026-09-30 0000880242blgo:PartiallyOwnedSubsidiaryMember2025-01-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-01-012026-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2025-01-012025-09-30 0000880242blgo:ClyraMedicalCommonStockMember2026-01-012026-09-30 0000880242blgo:ClyraMedicalCommonStockMember2025-01-012025-09-30 xbrli:pure 0000880242blgo:ClyraMedicalTechnologiesMember2026-09-30 0000880242blgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2026-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMember2026-09-30 0000880242srt:ParentCompanyMember2026-09-30 0000880242srt:ParentCompanyMember2025-12-31 0000880242us-gaap:NoncontrollingInterestMember2026-09-30 0000880242us-gaap:NoncontrollingInterestMember2025-12-31 0000880242blgo:RoyaltyReceivableMemberus-gaap:FinancialAssetPastDueMember2025-06-06 0000880242us-gaap:FinancialAssetPastDueMemberblgo:ProductInvoiceReceivableMember2025-06-06 0000880242us-gaap:FinancialAssetPastDueMemberblgo:ProductInvoiceReceivableMember2025-06-062025-06-06 0000880242blgo:RoyaltyReceivableMember2025-08-05 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerAMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerAMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerAMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerAMember2025-01-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerBMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerBMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerBMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerBMember2025-01-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerCMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerCMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerCMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerCMember2025-01-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerDMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerDMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerDMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerDMember2025-01-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerEMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerEMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerEMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerEMember2025-01-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerFMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerFMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerFMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerFMember2025-01-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerGMember2026-07-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerGMember2025-07-012025-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerGMember2026-01-012026-09-30 0000880242us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerGMember2025-01-012025-09-30 0000880242us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerAMember2026-01-012026-09-30 0000880242us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerAMember2025-01-012025-12-31 0000880242us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerBMember2026-01-012026-09-30 0000880242us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerBMember2025-01-012025-12-31 0000880242us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerDMember2026-01-012026-09-30 0000880242us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberblgo:CustomerDMember2025-01-012025-12-31 00008802422021-10-22 0000880242us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0000880242us-gaap:WarrantMember2026-01-012026-09-30 0000880242blgo:NonPlanMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:MinimumMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:MaximumMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Member2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:MinimumMember2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:MaximumMember2025-01-012025-09-30 0000880242blgo:NonPlanMember2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2024Member2026-01-012026-09-30 utr:Y 0000880242blgo:ClyraMedicalTechnologiesMember2026-09-30 0000880242country:CA2025-12-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2025-12-31 utr:M 0000880242blgo:CanadianGovernmentGrantsMembersrt:MinimumMember2026-01-012026-09-30 0000880242blgo:CanadianGovernmentGrantsMembersrt:MaximumMember2026-01-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMember2025-12-31 0000880242srt:MinimumMember2026-09-30 0000880242srt:MaximumMember2026-09-30 0000880242us-gaap:EquipmentMember2026-09-30 0000880242us-gaap:EquipmentMember2025-12-31 0000880242us-gaap:LeaseholdImprovementsMember2026-09-30 0000880242us-gaap:LeaseholdImprovementsMember2025-12-31 0000880242blgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2025-12-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2025-12-31 0000880242blgo:LincolnParkCapitalFundLLCMember2026-01-012026-03-31 0000880242blgo:LincolnParkCapitalFundLLCMember2026-04-012026-06-30 0000880242blgo:LincolnParkCapitalFundLLCMember2025-07-012025-09-30 0000880242blgo:LincolnParkCapitalFundLLCMember2025-01-012025-09-30 0000880242blgo:ClearthinkCapitalPartnersLlcMember2026-03-20 0000880242blgo:ClearthinkCapitalPartnersLlcMember2026-01-012026-03-31 0000880242blgo:ClearthinkCapitalPartnersLlcMember2026-03-31 0000880242blgo:ClearthinkCapitalPartnersLlcMember2026-04-152026-09-30 0000880242blgo:UnitOfferingMember2026-01-012026-03-31 0000880242blgo:UnitOfferingMember2026-07-012026-09-30 0000880242blgo:TheSixMonthWarrantsIssuedInUnitOfferingsMember2026-09-30 0000880242blgo:TheFiveYearWarrantsIssuedInUnitOfferingsMember2026-09-30 0000880242blgo:UnitOfferingMember2025-01-012025-09-30 0000880242blgo:LincolnParkCapitalFundLLCMember2026-07-012026-09-30 0000880242blgo:UnitOfferingMember2026-01-012026-09-30 0000880242blgo:UnitOfferingMember2025-07-012025-09-30 0000880242blgo:PaycheckProtectionProgramCaresActMember2026-09-30 0000880242blgo:PaycheckProtectionProgramCaresActMember2025-12-31 0000880242blgo:VehicleLoanMember2026-09-30 0000880242blgo:VehicleLoanMember2025-12-31 0000880242blgo:TermLoanAgreementMember2026-09-30 0000880242blgo:TermLoanAgreementMember2025-12-31 0000880242blgo:SbaEidlLoanMember2026-09-30 0000880242blgo:SbaEidlLoanMember2025-12-31 0000880242blgo:DebtExcludingClyraMedicalTechnologiesMember2026-09-30 0000880242blgo:DebtExcludingClyraMedicalTechnologiesMember2025-12-31 0000880242blgo:EconomicInjuryDisasterLoanMember2026-09-30 0000880242blgo:EconomicInjuryDisasterLoanMember2025-12-31 0000880242blgo:VehicleLoanMember2023-02-07 0000880242blgo:VehicleLoanMember2023-02-072023-02-07 0000880242blgo:TermLoanAgreementMember2025-04-05 0000880242blgo:TermLoanAgreementMember2025-04-052025-04-05 0000880242blgo:PaycheckProtectionProgramCaresActMemberblgo:ONMMember2022-02-072022-02-07 0000880242blgo:PaycheckProtectionProgramCaresActMemberblgo:ONMMember2026-09-30 0000880242blgo:PaycheckProtectionProgramCaresActMemberblgo:ONMMember2025-12-31 0000880242blgo:EconomicInjuryDisasterLoanMemberblgo:ONMMember2020-07-31 0000880242blgo:EconomicInjuryDisasterLoanMemberblgo:ONMMember2020-07-012020-07-31 0000880242blgo:EconomicInjuryDisasterLoanMemberblgo:ONMMember2026-09-30 0000880242blgo:EconomicInjuryDisasterLoanMemberblgo:ONMMember2025-12-31 0000880242srt:OfficerMember2026-07-012026-09-30 0000880242srt:OfficerMember2026-09-30 0000880242srt:OfficerMember2026-04-012026-06-30 0000880242srt:OfficerMember2026-06-30 0000880242srt:OfficerMember2026-01-012026-03-31 0000880242srt:OfficerMember2026-03-31 0000880242srt:OfficerMember2025-07-012025-09-30 0000880242srt:OfficerMember2025-09-30 0000880242srt:OfficerMember2025-04-012025-06-30 0000880242srt:OfficerMember2025-06-30 0000880242srt:OfficerMember2025-01-012025-03-31 0000880242srt:OfficerMember2025-03-31 0000880242blgo:ConsultantsAndVendorsMember2026-07-012026-09-30 0000880242blgo:ConsultantsAndVendorsMember2026-09-30 0000880242blgo:ConsultantsAndVendorsMember2026-04-012026-06-30 0000880242blgo:ConsultantsAndVendorsMember2026-06-30 0000880242blgo:ConsultantsAndVendorsMember2026-01-012026-03-31 0000880242blgo:ConsultantsAndVendorsMember2026-03-31 0000880242blgo:ConsultantsAndVendorsMember2025-07-012025-09-30 0000880242blgo:ConsultantsAndVendorsMember2025-09-30 0000880242blgo:ConsultantsAndVendorsMember2025-04-012025-06-30 0000880242blgo:ConsultantsAndVendorsMember2025-06-30 0000880242blgo:ConsultantsAndVendorsMember2025-01-012025-03-31 0000880242blgo:ConsultantsAndVendorsMember2025-03-31 0000880242us-gaap:EmployeeStockOptionMember2026-07-012026-09-30 0000880242us-gaap:EmployeeStockOptionMember2026-01-012026-09-30 0000880242us-gaap:EmployeeStockOptionMember2025-07-012025-09-30 0000880242us-gaap:EmployeeStockOptionMember2025-01-012025-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalTechnologiesMember2026-07-012026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalTechnologiesMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Member2026-09-30 0000880242blgo:EquityIncentivePlan2024Member2024-12-31 0000880242blgo:EquityIncentivePlan2024Member2025-09-30 0000880242blgo:EquityIncentivePlan2024Member2025-12-31 0000880242blgo:EquityIncentivePlan2024Memberblgo:BoardOfDirectorsEmployeesAndConsultantsMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:DirectorMember2026-01-012026-09-30 0000880242blgo:EmployeeRetentionProgramMemberblgo:EquityIncentivePlan2024Memberblgo:EmployeesMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Memberblgo:ConsultantsMember2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:ChiefFinancialOfficerMember2026-01-012026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:EquityIncentivePlan2024Member2026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:EquityIncentivePlan2024Member2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2024Memberblgo:BoardOfDirectorsEmployeesAndConsultantsMember2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:DirectorMember2025-01-012025-09-30 0000880242blgo:EmployeeRetentionProgramMemberblgo:EquityIncentivePlan2024Memberblgo:EmployeesMember2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2024Memberblgo:ConsultantsMember2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2024Membersrt:ChiefFinancialOfficerMember2025-01-012025-09-30 0000880242us-gaap:EmployeeStockOptionMembersrt:ChiefFinancialOfficerMember2026-01-312026-01-31 00008802422026-01-31 0000880242us-gaap:EmployeeStockOptionMembersrt:ChiefFinancialOfficerMember2025-01-312025-01-31 00008802422025-01-31 0000880242blgo:EquityIncentivePlan2018Member2018-06-222018-06-22 0000880242blgo:EquityIncentivePlan2018Member2024-06-30 0000880242blgo:EquityIncentivePlan2018Member2024-12-31 0000880242blgo:EquityIncentivePlan2018Member2025-01-012025-09-30 0000880242blgo:EquityIncentivePlan2018Member2025-09-30 0000880242blgo:EquityIncentivePlan2018Member2025-12-31 0000880242blgo:EquityIncentivePlan2018Member2026-01-012026-09-30 0000880242blgo:EquityIncentivePlan2018Member2026-09-30 0000880242blgo:EquityIncentivePlan2007Member2017-09-072017-09-07 0000880242blgo:The2007EquityIncentivePlanMember2024-12-31 0000880242blgo:The2007EquityIncentivePlanMember2025-01-012025-09-30 0000880242blgo:The2007EquityIncentivePlanMember2025-09-30 0000880242blgo:The2007EquityIncentivePlanMember2025-12-31 0000880242blgo:The2007EquityIncentivePlanMember2026-01-012026-09-30 0000880242blgo:The2007EquityIncentivePlanMembersrt:MinimumMember2026-01-012026-09-30 0000880242blgo:The2007EquityIncentivePlanMember2026-09-30 0000880242blgo:NonPlanMember2024-12-31 0000880242blgo:NonPlanMember2025-09-30 0000880242blgo:NonPlanMember2025-12-31 0000880242blgo:NonPlanMember2026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:NonPlanMember2026-01-012026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:NonPlanMember2025-01-012025-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:NonPlanMember2025-09-30 0000880242srt:WeightedAverageMember2024-12-31 0000880242srt:WeightedAverageMember2025-01-012025-09-30 0000880242srt:WeightedAverageMember2025-09-30 0000880242srt:WeightedAverageMember2025-12-31 0000880242srt:WeightedAverageMember2026-01-012026-09-30 0000880242srt:WeightedAverageMember2026-09-30 0000880242blgo:WarrantsIssuedInUnitOfferingsMember2025-01-012025-09-30 0000880242us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2026-09-30 0000880242us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2026-09-30 0000880242us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MinimumMember2025-12-31 0000880242us-gaap:MeasurementInputRiskFreeInterestRateMembersrt:MaximumMember2025-12-31 0000880242us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2026-09-30 0000880242us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2026-09-30 0000880242us-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2025-12-31 0000880242us-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2025-12-31 0000880242us-gaap:MeasurementInputExpectedDividendRateMember2026-09-30 0000880242us-gaap:MeasurementInputExpectedDividendRateMember2025-12-31 0000880242blgo:MeasurementInputForfeitureRateMember2026-09-30 0000880242blgo:MeasurementInputForfeitureRateMembersrt:MaximumMember2025-12-31 0000880242us-gaap:CorporateNonSegmentMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:OdorNoMoreMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BLESTMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoCanadaMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEnergyTechnologiesIncBETIMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BestMember2026-09-30 0000880242srt:ConsolidationEliminationsMember2026-09-30 0000880242us-gaap:CorporateNonSegmentMember2025-12-31 0000880242us-gaap:OperatingSegmentsMemberblgo:OdorNoMoreMember2025-12-31 0000880242us-gaap:OperatingSegmentsMemberblgo:BLESTMember2025-12-31 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoCanadaMember2025-12-31 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEnergyTechnologiesIncBETIMember2025-12-31 0000880242us-gaap:OperatingSegmentsMemberblgo:BestMember2025-12-31 0000880242srt:ConsolidationEliminationsMember2025-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMember2024-01-012024-12-31 0000880242blgo:BiolargoMemberblgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMember2024-01-012024-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMember2024-12-31 0000880242blgo:WarrantInConnectionWithConvertibleNoteMemberblgo:ClyraMedicalMember2024-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMember2025-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMember2026-09-30 0000880242blgo:WarrantsIssuedConcurrentlyWithNotePayableMemberblgo:ClyraMedicalMember2026-09-30 0000880242blgo:BiolargoMemberblgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMember2026-09-30 0000880242blgo:ClyraMedicalMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:SubsequentEventMember2026-10-01 0000880242blgo:ClyraMedicalMemberus-gaap:ConvertibleDebtMember2026-09-30 0000880242blgo:ClyraMedicalMemberus-gaap:ConvertibleDebtMember2026-07-012026-09-30 0000880242blgo:WarrantInConnectionWithConvertibleNoteMemberblgo:ClyraMedicalMember2026-09-30 0000880242blgo:ClyraMedicalMemberus-gaap:ConvertibleDebtMember2026-06-30 0000880242blgo:ClyraMedicalMemberus-gaap:ConvertibleDebtMember2026-01-012026-06-30 0000880242blgo:WarrantInConnectionWithConvertibleNoteMemberblgo:ClyraMedicalMember2026-06-30 0000880242blgo:ClyraMedicalMemberus-gaap:ConvertibleDebtMember2025-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:ConvertibleDebtMember2025-01-012025-12-31 0000880242blgo:WarrantsIssuedConcurrentlyWithNotePayableMemberblgo:ClyraMedicalMember2025-12-31 0000880242blgo:WarrantInConnectionWithGuaranteedNoteMemberblgo:ClyraMedicalMember2025-12-31 0000880242us-gaap:RevolvingCreditFacilityMemberblgo:InventoryLineOfCreditMemberblgo:ClyraMedicalMemberblgo:VernalBayCapitalGroupLLCMember2026-09-30 0000880242us-gaap:RevolvingCreditFacilityMemberblgo:InventoryLineOfCreditMemberblgo:ClyraMedicalMemberblgo:VernalBayCapitalGroupLLCMember2020-06-302026-06-30 0000880242us-gaap:RevolvingCreditFacilityMemberblgo:InventoryLineOfCreditMemberblgo:ClyraMedicalMemberblgo:VernalBayCapitalGroupLLCMember2025-12-31 0000880242blgo:ClyraMedicalMember2026-09-30 0000880242blgo:ClyraMedicalMember2025-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesAPreferredStockMember2026-09-30 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesAPreferredStockMember2025-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesBPreferredStockMember2026-09-30 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesBPreferredStockMember2025-12-31 0000880242us-gaap:CommonStockMemberblgo:ClyraMedicalMember2026-09-30 0000880242us-gaap:CommonStockMemberblgo:ClyraMedicalMember2025-12-31 0000880242blgo:PreferredStockSeriesAMemberblgo:ClyraMedicalMember2026-09-30 0000880242blgo:PreferredStockSeriesAMemberblgo:ClyraMedicalMember2025-12-31 0000880242blgo:ClyraMedicalMemberus-gaap:PreferredClassAMember2023-10-012023-10-31 0000880242blgo:WarrantsIssuedInConjunctionWithTheSaleOfSeriesAPreferredStockMemberblgo:ClyraMedicalMember2023-10-31 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesAPreferredStockMember2023-10-012023-10-31 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesAPreferredStockMember2023-10-31 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesAPreferredStockMember2026-01-012026-09-30 0000880242blgo:ClyraMedicalMemberus-gaap:SeriesAPreferredStockMember2025-01-012025-12-31 0000880242blgo:ClyraMedicalTechnologiesMemberus-gaap:SeriesBPreferredStockMember2025-10-012025-10-31 0000880242blgo:WarrantsIssuedInOctober2025OfferingMemberblgo:ClyraMedicalTechnologiesMember2025-10-31 0000880242blgo:ClyraMedicalTechnologiesMember2026-01-012026-09-30 0000880242blgo:ClyraMedicalTechnologiesMember2025-01-012025-09-30 0000880242blgo:March312025WarrantsMemberblgo:ClyraMedicalTechnologiesMember2025-01-012025-09-30 0000880242blgo:March312025WarrantsMemberblgo:ClyraMedicalTechnologiesMember2025-09-30 0000880242blgo:ClyraMedicalMemberblgo:VendorsMember2026-07-012026-09-30 0000880242blgo:ClyraMedicalMemberblgo:VendorsMember2025-01-012025-09-30 0000880242blgo:VendorWarrantsMemberblgo:ClyraMedicalMember2025-01-012025-09-30 0000880242blgo:VendorWarrantsMemberblgo:ClyraMedicalMember2025-09-30 0000880242blgo:ClyraMedicalMember2024-12-31 0000880242blgo:ClyraMedicalMember2025-01-012025-09-30 0000880242blgo:ClyraMedicalMember2025-09-30 0000880242blgo:ClyraMedicalMember2026-01-012026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalMemberblgo:EmployeesAndConsultantsMember2026-01-012026-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalMemberblgo:EmployeesAndConsultantsMember2025-01-012025-09-30 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalMemberblgo:EmployeesAndConsultantsMember2026-03-31 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalMemberblgo:EmployeesAndConsultantsMember2026-01-012026-03-31 0000880242us-gaap:EmployeeStockOptionMemberblgo:ClyraMedicalMemberblgo:EmployeesAndConsultantsMember2026-09-30 0000880242srt:MinimumMember2026-01-012026-09-30 0000880242srt:MaximumMember2026-01-012026-09-30 0000880242srt:MinimumMember2025-01-012025-09-30 0000880242srt:MaximumMember2025-01-012025-09-30 0000880242blgo:ClyraMedicalMembersrt:MinimumMember2024-12-31 0000880242blgo:ClyraMedicalMembersrt:MinimumMember2025-01-012025-09-30 0000880242blgo:ClyraMedicalMembersrt:MinimumMember2025-09-30 0000880242blgo:ClyraMedicalMembersrt:MinimumMember2025-12-31 0000880242blgo:ClyraMedicalMembersrt:MinimumMember2026-01-012026-09-30 0000880242blgo:ClyraMedicalMembersrt:MinimumMember2026-09-30 0000880242blgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2024-12-042024-12-04 0000880242blgo:PromissoryNoteMemberblgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2024-12-04 0000880242blgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2024-12-04 0000880242blgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2026-09-30 0000880242blgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2026-09-102026-09-10 0000880242blgo:PromissoryNoteMemberblgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2026-09-10 0000880242blgo:PromissoryNoteMemberblgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2026-09-102026-09-10 0000880242blgo:ClyraMedicalMemberblgo:SaleLeasebackOfEquipmentMember2026-09-10 0000880242blgo:ClyraLeaseWarrantMemberblgo:ClyraMedicalMember2026-09-10 0000880242blgo:ClyraLeaseWarrantMemberblgo:ClyraMedicalMember2026-09-102026-09-10 0000880242blgo:ClyraLeaseWarrantMemberblgo:ClyraMedicalMemberus-gaap:MeasurementInputSharePriceMember2026-09-10 0000880242blgo:ClyraLeaseWarrantMemberblgo:ClyraMedicalMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MinimumMember2026-09-10 0000880242blgo:ClyraLeaseWarrantMemberblgo:ClyraMedicalMemberus-gaap:MeasurementInputPriceVolatilityMembersrt:MaximumMember2026-09-10 0000880242blgo:ClyraLeaseWarrantMemberblgo:ClyraMedicalMemberus-gaap:MeasurementInputDiscountRateMember2026-09-10 0000880242blgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2017-09-30 0000880242blgo:NonqualifiedStockOptionMemberblgo:SevenEmployeesWorkingAtBiolargoEngineeringScienceTechnologiesLLCMember2017-09-012017-09-30 0000880242blgo:SevenEmployeesWorkingAtBiolargoEngineeringScienceTechnologiesLLCMemberblgo:VestingOnPerformanceMetricsMember2026-01-012026-09-30 0000880242blgo:SevenEmployeesWorkingAtBiolargoEngineeringScienceTechnologiesLLCMemberblgo:VestingOnPerformanceMetricsMember2025-01-012025-12-31 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2023-01-01 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-01-012026-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2026-07-012026-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2025-01-012025-09-30 0000880242blgo:BiolargoEnergyTechnologiesIncBETIMember2025-09-30 0000880242blgo:ConversionOfBetiCommonStockToBiolargoCommonStockMember2025-01-012025-09-30 0000880242blgo:ConversionOfIntercompanyPayablesToBetiCommonStockMember2026-07-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMember2026-01-012026-09-30 0000880242blgo:BiolargoConsumerProductsGroupBcpgMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:OdorNoMoreMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:OdorNoMoreMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:OdorNoMoreMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:OdorNoMoreMember2025-01-012025-09-30 0000880242us-gaap:CorporateNonSegmentMember2026-07-012026-09-30 0000880242us-gaap:CorporateNonSegmentMember2025-07-012025-09-30 0000880242us-gaap:CorporateNonSegmentMember2026-01-012026-09-30 0000880242us-gaap:CorporateNonSegmentMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:ClyraSegmentMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:ClyraSegmentMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:ClyraSegmentMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:ClyraSegmentMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoCanadaMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoCanadaMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoCanadaMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoCanadaMember2025-01-012025-09-30 0000880242srt:ConsolidationEliminationsMember2026-07-012026-09-30 0000880242srt:ConsolidationEliminationsMember2025-07-012025-09-30 0000880242srt:ConsolidationEliminationsMember2026-01-012026-09-30 0000880242srt:ConsolidationEliminationsMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEnergyTechnologiesIncBETIMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEnergyTechnologiesIncBETIMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEnergyTechnologiesIncBETIMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEnergyTechnologiesIncBETIMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoConsumerProductsGroupBcpgMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoConsumerProductsGroupBcpgMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoConsumerProductsGroupBcpgMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoConsumerProductsGroupBcpgMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BestMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BestMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BestMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BestMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BLESTMember2026-07-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BLESTMember2025-07-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BLESTMember2026-01-012026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BLESTMember2025-01-012025-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:ClyraSegmentMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoConsumerProductsGroupBcpgMember2026-09-30 0000880242us-gaap:OperatingSegmentsMemberblgo:ClyraSegmentMember2025-12-31 0000880242us-gaap:OperatingSegmentsMemberblgo:BiolargoEngineeringScienceTechnologiesLLCBLESTMember2025-12-31 0000880242blgo:BiolargoONMLeaseMember2026-09-30 0000880242blgo:ClyraOfficeLeaseMember2026-09-30 0000880242blgo:BLESTLeaseMember2026-09-30 0000880242blgo:LawsuitAgainstPoophIncCompensatoryDamagesForUnpaidRoyaltiesMemberus-gaap:PendingLitigationMember2025-11-112025-11-11 0000880242blgo:ClearthinkCapitalPartnersLlcMemberus-gaap:SubsequentEventMember2026-10-012026-10-01 00008802422026-10-012026-10-01 0000880242blgo:ClyraMedicalMemberus-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2026-10-01 0000880242blgo:WarrantsIssuedWithGuaranteedPromissoryNoteMemberblgo:ClyraMedicalMemberus-gaap:SubsequentEventMember2026-10-01 0000880242blgo:SafeInstrumentsMemberus-gaap:SubsequentEventMember2026-10-01 0000880242blgo:DebtExtensionWarrantsMemberblgo:ClyraMedicalMemberus-gaap:SubsequentEventMember2026-10-01 0000880242srt:ScenarioForecastMemberblgo:VicePresidentOfOperationsMember2026-11-132027-11-13
 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2026.

 

or

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from              to             

Commission File Number 000-19709

 


 

BIOLARGO, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware

 

65-0159115

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

 

14921 Chestnut St.

Westminster, CA 92683

(Address of principal executive offices)

 

(888) 400-2863

(Registrant’s telephone number, including area code)

 


 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common stock

BLGO

OTC Markets (OTCQX)

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐Accelerated filer ☐
  
Non-accelerated filer   ☒Smaller reporting company ☒
  
 Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.         ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒

 

The number of shares of the Registrant’s Common Stock outstanding as of November 12, 2026 was 338,443,806 shares.  

 

 

 

 

BIOLARGO, INC.

FORM 10-Q

INDEX

 

PART I

 

Item 1

Financial Statements

1
     

Item 2

Management's Discussion and Analysis of Financial Condition and Results of Operations

25
     

Item 4

Controls and Procedures

32

 

PART II

 

Item 1 Legal Proceedings 33
     

Item 2

Unregistered Sales of Equity Securities and Use of Proceeds

33
     

Item 5

Other Information

33
     

Item 6

Exhibits

34
     
 

Signatures

36

 

 

 

 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

- 1 -

 

 

BIOLARGO, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except for share and per share data)

 

  

September 30, 2026

  

December 31,

 
  

(unaudited)

  

2025

 

Assets

 

Current assets:

        

Cash and cash equivalents

 $1,533  $3,883 

Accounts receivable, net of allowances

  1,417   615 

Inventories

  322   310 

Prepaid expenses and other current assets

  273   306 

Total current assets

  3,545   5,114 
         

Equipment and leasehold improvements, net

  1,682   1,643 

Other non-current assets

  116   106 

Operating lease right-of-use assets, net

  992   1,028 

Financing lease right-of-use asset, net

  254   338 

Clyra Medical note receivable

  625   82 

Total assets

 $7,214  $8,311 
         

Liabilities and stockholders’ equity

 

Current liabilities:

        

Accounts payable and accrued expenses

 $1,415  $1,211 

Clyra Medical accounts payable and accrued expenses

  2,122   1,592 

Clyra Medical debt obligations, net of discount $34 and $139

  1,366   1,395 

Contract liabilities

  615   280 

Debt obligations

  82   83 

Operating lease liabilities

  216   210 

Finance lease liability

  115   103 

Deposits

  5   189 

Total current liabilities

  5,936   5,063 
         

Long-term liabilities:

        

Debt obligations, net of current

  157   182 

Clyra Medical debt obligations, net of current and discount $441 and $56

  4,876   419 

Operating lease liabilities, net of current

  826   864 

Finance lease liability, net of current

  170   257 

Total long-term liabilities

  6,029   1,722 

Total liabilities

  11,965   6,785 
         
         

STOCKHOLDERS’ (DEFICIT) EQUITY:

        

Preferred Series A, $0.00067 Par Value, 50,000,000 Shares Authorized, no Shares Issued and Outstanding, at September 30, 2026 and December 31, 2025

  —   — 

Common stock, $0.00067 Par Value, 550,000,000 Shares Authorized, 334,843,806 and 317,377,777 Shares Issued, at September 30, 2026 and December 31, 2025

  224   213 

Additional paid-in capital

  163,665   165,316 

Accumulated deficit

  (168,935)  (161,280)

Accumulated other comprehensive loss

  (215)  (207)

Total BioLargo Inc. and subsidiaries stockholders’ (deficit) equity

  (5,261)  4,042 

Non-controlling interest (Notes 8, 9, 10, 11)

  510   (2,516)

Total stockholders’ (deficit) equity

  (4,751)  1,526 

Total liabilities and stockholders’ equity

 $7,214  $8,311 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

- 2 -

 

 

BIOLARGO, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except for share and per share data)

(unaudited)

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2026

  

2025

  

2026

  

2025

 
                 

Revenue

                

Product revenue

 $527  $776  $1,525  $5,584 

Service revenue

  563   327   1,927   1,564 

   Total revenue

  1,090   1,103   3,452   7,148 
                 

Cost of revenue

                

Cost of goods sold

  (158)  (418)  (552)  (2,837)

Cost of service

  (416)  (313)  (1,251)  (1,033)

   Total cost of revenue

  (574)  (731)  (1,803)  (3,870)
                 

Gross profit

  516   372   1,649   3,278 
                 

Selling, general and administrative expenses

  3,228   3,088   9,298   8,339 

Research and development

  810   615   2,805   1,934 

Credit loss expense

  —   3,849   —   3,849 

   Total operating expenses

  4,038   7,552   12,103   14,122 

      Operating loss

  (3,522)  (7,180)  (10,454)  (10,844)
                 

Other income (expense):

                

Interest expense

  (317)  (144)  (790)  (352)

Interest income

  15   80   100   143 

Finance fee

  —   —   (85)  — 

Grant income

  —   —   —   6 

   Total other expense

  (302)  (64)  (775)  (203)

      Net loss

  (3,824)  (7,244)  (11,229)  (11,047)
                 

Net loss attributable to noncontrolling interest

  (1,222)  (765)  (3,574)  (2,220)

Net loss attributable to common shareholders

 $(2,602) $(6,479) $(7,655) $(8,827)
                 

Net loss per share attributable to common shareholders:

                

Loss per share attributable to shareholders – basic and diluted

 $(0.01) $(0.02) $(0.02) $(0.03)

Weighted average number of common shares outstanding:

  329,077,297   308,974,027   322,957,874   304,509,957 
                 

Comprehensive loss:

                

Net loss

 $(3,824) $(7,244) $(11,229) $(11,047)

Foreign currency translation

  (9)  8   (8)  (12)

Comprehensive loss

  (3,833)  (7,236)  (11,237)  (11,059)

Comprehensive loss attributable to noncontrolling interest

  (1,222)  (765)  (3,574)  (2,220)

Comprehensive loss attributable to common stockholders

 $(2,611) $(6,471) $(7,663) $(8,839)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

- 3 -

 

 

BIOLARGO, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

(in thousands, except for share data)

 

  

Common stock

  

Additional paid-in

  

Accumulated

  

Accumulated other comprehensive

  

Non-controlling

  

Total stockholders’

 
  

Shares

  

Amount

  

capital

  

deficit

  

loss

  

interest

  

equity

 

Balance, December 31, 2025

  317,377,777  $213  $165,316  $(161,280) $(207) $(2,516) $1,526 

Sale of common stock for cash, net of offering costs of $15 (unaudited)

  1,539,744   1   255   —   —   —   256 

Issuance of common stock for services (unaudited)

  282,407   —   46   —   —   —   46 

Stock option compensation expense (unaudited)

  —   —   286   —   —   —   286 

Common stock issued as a fee (unaudited)

  500,000   —   85   —   —   —   85 

Clyra Medical stock option compensation expense (unaudited)

  —   —   —   —   —   413   413 

Clyra Medical dividend Series A Preferred stock (unaudited)

  —   —   —   —   —   (86)  (86)

Clyra Medical fair value warrant issued with debt (unaudited)

  —   —   —   —   —   232   232 

BETI unit offering (unaudited)

  —   —   —   —   —   462   462 

Noncontrolling interest allocation (unaudited)

  —   —   (641)  —   —   641   — 

Net loss (unaudited)

  —   —   —   (2,286)  —   (1,119)  (3,405)

Foreign currency translation (unaudited)

  —   —   —   —   (2)  —   (2)

Balance, March 31, 2026 (unaudited)

  319,699,928  $214  $165,347  $(163,566) $(209) $(1,973) $(187)

Sale of common stock for cash (unaudited)

  3,250,000   2   389   —   —   —   391 

Issuance of common stock for services (unaudited)

  2,281,434   1   235   —   —   —   236 

Stock option compensation expense (unaudited)

  —   —   472   —   —   —   472 

Clyra Medical stock option compensation expense (unaudited)

  —   —   —   —   —   250   250 

Clyra Medical stock issued for services (unaudited)

  —   —   —   —   —   17   17 

Clyra Medical stock option exercise (unaudited)

  —   —   —   —   —   5   5 

Clyra Medical dividend Series A Preferred stock (unaudited)

  —   —   —   —   —   (87)  (87)

Clyra Medical fair value warrant issued with debt (unaudited)

  —   —   —   —   —   121   121 

BETI unit offering (unaudited)

  —   —   —   —   —   25   25 

BETI stock issued for services (unaudited)

  —   —   —   —   —   4   4 

BCPG stock issued for services (unaudited)

  —   —   —   —   —   20   20 

Noncontrolling interest allocation (unaudited)

  —   —   (1,973)  —   —   1,973   — 

Net loss (unaudited)

  —   —   —   (2,767)  —   (1,233)  (4,000)

Foreign currency translation (unaudited)

  —   —   —   —   3   —   3 

Balance, June 30, 2026 (unaudited)

  325,231,362  $217  $164,470  $(166,333) $(206) $(878) $(2,730)

Sale of common stock for cash (unaudited)

  7,100,000   5   707   —   —   —   712 

Issuance of common stock for services (unaudited)

  2,512,444   2   213   —   —   —   215 

Stock option compensation expense (unaudited)

  —   —   401   —   —   —   401 

Clyra Medical stock option compensation expense (unaudited)

  —   —   —   —   —   426   426 

Clyra Medical dividend Series A Preferred stock (unaudited)

  —   —   —   —   —   (87)  (87)

Clyra Medical fair value warrant issued with debt (unaudited)

  —   —   —   —   —   138   138 

BCPG stock issued for services (unaudited)

  —   —   —   —   —   7   7 

Noncontrolling interest allocation (unaudited)

  —   —   (2,126)  —   —   2,126   — 

Net loss (unaudited)

  —   —   —   (2,602)  —   (1,222)  (3,824)

Foreign currency translation (unaudited)

  —   —   —   —   (9)  —   (9)

Balance, September 30, 2026 (unaudited)

  334,843,806   224   163,665   (168,935)  (215)  510   (4,751)

 

- 4 -

 

BIOLARGO, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ (DEFICIT) EQUITY

(in thousands, except for share data)

 

  

Common stock

  

Additional paid-in

  

Accumulated

  

Accumulated other comprehensive

  

Non-controlling

  

Total stockholders’

 
  

Shares

  

Amount

  

capital

  

deficit

  

loss

  

interest

  

equity

 

Balance, December 31, 2024

  301,274,243  $202  $158,332  $(149,500) $(183) $(2,795) $6,056 

Sale of common stock for cash, net of offering costs of $15 (unaudited)

  —   —   (15)  —   —   —   (15)

Issuance of common stock for services (unaudited)

  220,330   —   61   —   —   —   61 

Stock option compensation expense (unaudited)

  —   —   409   —   —   —   409 

Stock option exercise (unaudited)

  265,800   —   —   —   —   —   — 

Clyra Medical stock option compensation expense (unaudited)

  —   —   —   —   —   206   206 

Clyra Medical stock issued for services (unaudited)

  —   —   —   —   —   36   36 

Clyra Medical stock unit offering (unaudited)

  —   —   —   —   —   295   295 

Clyra Medical dividend Series A Preferred stock (unaudited)

  —   —   —   —   —   (86)  (86)

Clyra Medical fair value warrant issued with debt (unaudited)

  —   —   —   —   —   69   69 

Noncontrolling interest allocation (unaudited)

  —   —   (522)  —   —   522   — 

Net loss (unaudited)

  —   —   —   (1,155)  —   (766)  (1,921)

Foreign currency translation (unaudited)

  —   —   —   —   (20)  —   (20)

Balance, March 31, 2025 (unaudited)

  301,760,373  $202  $158,265  $(150,655) $(203) $(2,519) $5,090 

Sale of stock for cash, net offering costs of $15 (unaudited)

  4,077,285   3   805   —   —   —   808 

Issuance of common stock for services (unaudited)

  915,003   —   212   —   —   —   212 

Stock option compensation expense (unaudited)

  —   —   292   —   —   —   292 

Clyra Medical stock option compensation expense (unaudited)

  —   —   —   —   —   200   200 

Clyra Medical stock issued for services (unaudited)

  —   —   —   —   —   24   24 

Clyra Medical dividend Series A Preferred stock (unaudited)

  —   —   —   —   —   (86)  (86)

Clyra Medical fair value warrant issued with debt (unaudited)

  —   —   —   —   —   93   93 

Clyra Medical Unit Warrant offering (unaudited)

  —   —   —   —   —   1,309   1,309 

Noncontrolling interest allocation (unaudited)

  —   —   1,027   —   —   (1,027)  — 

Net loss (unaudited)

  —   —   —   (1,193)  —   (689)  (1,882)

Balance, June 30, 2025 (unaudited)

  306,752,661  $205  $160,601  $(151,848) $(203) $(2,695) $6,060 

Sale of stock for cash, net offering costs of $15 (unaudited)

  4,222,467   3   746   —   —   —   749 

Issuance of common stock for services (unaudited)

  324,294   —   55   —   —   —   55 

Stock option compensation expense (unaudited)

  —   —   651   —   —   —   651 

Exchange of BETI stock for BioLargo common stock (unaudited)

  153,261   —   —   —   —   —   — 

Clyra Medical stock option compensation expense (unaudited)

  —   —   —   —   —   193   193 

Clyra Medical dividend Series B Preferred stock (unaudited)

  —   —   —   —   —   2,145   2,145 

Clyra Medical dividend Series A Preferred stock (unaudited)

  —   —   —   —   —   (87)  (87)

Clyra Medical Unit Warrant offering (unaudited)

  —   —   —   —   —   585   585 

BETI unit offering (unaudited)

  —   —   —   —   —   100   100 

Noncontrolling interest allocation (unaudited)

  —   —   2,841   —   —   (2,841)  — 

Net loss (unaudited)

  —   —   —   (6,479)  —   (765)  (7,244)

Foreign currency translation (unaudited)

  —   —   —   —   8   —   8 

Balance, September 30, 2025 (unaudited)

  311,452,683  $208  $164,894  $(158,327) $(195) $(3,365) $3,215 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

- 5 -

 

 

BIOLARGO, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands, except for share and per share data)

(unaudited)

 

  

Nine Months Ended September 30,

 
  

2026

  

2025

 

Cash flows from operating activities

        

Net loss

 $(11,229) $(11,047)

Adjustments to reconcile net loss to net cash used in operating activities:

        

Credit loss expense

  —   3,849 

Stock option compensation expense

  2,248   1,951 

Common stock issued for services

  545   388 

Bad debt expense

  13   37 

Amortization of debt discount

  211   106 

Amortization of right-of-use operating lease assets

  36   106 

Amortization of right-of-use finance lease asset

  84   51 

Operating lease liabilities

  (33)  (100)

Finance lease liability

  (75)  (65)

Gain on investment in South Korean joint venture

  —   (9)

Depreciation expense

  196   112 

Changes in assets and liabilities:

        

Accounts receivable

  (815)  (1,958)

Inventories

  (12)  (79)

Prepaid expenses and other assets

  23   11 

Accounts payable and accrued expenses

  204   (55)

Deposits

  (184)  (10)

Clyra Medical accounts payable and accrued expenses

  271   5 

Contract liabilities

  335   — 

Net cash used in operating activities

  (8,182)  (6,707)

Cash flows from investing activities

        

Equipment purchases

  (235)  (33)

Proceeds from note receivable

  —   481 

Net cash (used in) provided by investing activities

  (235)  448 

Cash flows from financing activities

        

Proceeds from sale of common stock, net of offering costs

  1,359   1,542 

Proceeds from note payable

  —   50 

Common stock issued for financing fee

  85   — 

Repayment of debt obligations

  (26)  (18)

Proceeds from BETI unit offering

  487   100 

Proceeds from Clyra Medical debt obligations

  4,299   1,261 

Proceeds from Clyra Medical preferred Series B

  —   2,145 

Repayment of Clyra Medical line of credit

  (134)  — 

Proceeds from Clyra Medical stock option exercise

  5   — 

Proceeds from Clyra Medical unit warrant offering

  —   1,894 

Proceeds from sales of Clyra Medical common stock

  —   295 

Net cash provided by financing activities

  6,075   7,269 

Net effect of foreign currency translation

  (8)  (12)

Net change in cash

  (2,350)  998 

Cash and cash equivalents at beginning of period

  3,883   3,548 

Cash and cash equivalents at end of period

 $1,533  $4,546 

Supplemental disclosures of cash flow information

        

Cash paid during the period for:

        

Interest

 $579  $264 

Income taxes

 $—  $— 

Short-term lease payments not included in lease liabilities

 $24  $21 

Non-cash investing and financing activities

        

Clyra Medical note receivable in connection with issuance of financing note payable

 $543  $— 

Conversion of accounts receivable to a note receivable

 $—  $3,764 

Allocation of noncontrolling interest

 $(4,740) $3,346 

Fair value of Clyra Medical warrants issued as debt discount

 $491  $162 

Clyra Medical dividend Series A Preferred stock

 $260  $259 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 
- 6 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

 

 

Note 1. Business and Organization

 

Description of Business

 

BioLargo, Inc. (“BioLargo”, or the “Company”) invents, develops, and commercializes cleantech innovative platform technologies to solve challenging environmental problems like PFAS contamination (per- and polyfluoroalkyl substances), advanced water and wastewater treatment, industrial odor control, air quality control, infection control, and myriad environmental remediation challenges. Our business strategy is straightforward: we invent or acquire technologies that we believe have the potential to be disruptive in large commercial markets; we develop and validate these technologies to advance and promote their commercial success as we leverage our considerable scientific, engineering, and entrepreneurial talent; we then monetize these technical assets through a variety of business structures that may include licensure, joint venture, sale, spin off, or by deploying direct to market strategies.

 

Organization

 

We are a Delaware corporation formed in 1991, and have five wholly-owned subsidiaries: BioLargo Life Technologies, Inc., organized under the laws of the State of California in 2006; ONM Environmental, Inc., organized under the laws of the State of California in 2009; BioLargo Equipment Solutions & Technologies, Inc., organized under the laws of the State of California in 2022; BioLargo Canada, Inc., organized under the laws of Canada in 2014; and BioLargo Development Corp., organized under the laws of the State of California in 2016. Additionally, we own 46% (see Note 8) of Clyra Medical Technologies, Inc. (“Clyra” or “Clyra Medical”), organized under the laws of the State of California in 2012 and redomiciled to Delaware in 2023; 70% (see Note 9) of BioLargo Engineering Science and Technologies, LLC (“BLEST"), organized under the laws of the State of Tennessee in 2017; and 93% (see Note 10) of BioLargo Energy Technologies, Inc. ("BETI") organized under the laws of the State of California in 2019; and 78% (See Note 11) of BioLargo CPG LLC ("BCPG") organized under the laws of the State of California in 2026. We consolidate the financial statements of our partially owned subsidiaries.

 

Liquidity / Going Concern

 

For the nine months ended September 30, 2026, we generated revenues of $3,452,000, had a net loss of $11,229,000, used $8,182,000 net cash in operating activities, and received $6,075,000 net cash from financing activities, of which 77% was received through subsidiary financings. As of  September 30, 2026, we had current assets of $3,545,000, including $1,533,000 cash and cash equivalents. As of September 30, 2026, we had current liabilities of $5,936,000, and working capital deficit of $2,391,000. Given the history of the Company's recurring losses, negative cash flow, and uncertainty related to operational revenues and gross profits in future periods, it is unknown whether gross profits in the next twelve months will be sufficient to fund our operational costs, and therefore expect we will continue to need further investment capital to fund our business plans and investments in our technologies. The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to increase revenues, generate gross profits from operations, and/or generate cash from financing activities. If we are unable to raise additional cash through gross profits or financing activities, management may choose to curtail portions of our operations. The condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

Note 2. Summary of Significant Accounting Policies

 

Principles of Consolidation

 

The condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiaries, and partially owned subsidiaries. All intercompany accounts and transactions have been eliminated.

 

The accounting and financial reporting policies of the Company conform, in all material respects, to accounting principles generally accepted in the United States of America (“GAAP”) and to general practices within the industry. The condensed consolidated financial statements in the Quarterly Report on Form 10-Q have not been audited by an independent registered public accounting firm, but in the opinion of management, reflect all necessary adjustments for a fair presentation of the Company’s condensed consolidated financial position and condensed consolidated results of operations. All adjustments were of a normal and recurring nature. The condensed consolidated financial statements have been prepared in accordance with GAAP and with the instructions to Form 10-Q adopted by the Securities and Exchange Commission (the “SEC”). Accordingly, the condensed consolidated financial statements do not include all information and footnotes required by GAAP for complete financial presentation and should be read in conjunction with our consolidated financial statements, and notes thereto, for the year ended  December 31, 2025, included in our Annual Report on Form 10-K filed with the SEC on March 4, 2026. The results of operations for the nine months ended September 30, 2026, are not necessarily indicative of the results to be expected for the full year or any future period.

 

Foreign Currency

 

The Company has designated the functional currency of BioLargo Canada, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, translation gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive loss.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with maturities of three months or less when acquired to be cash equivalents. Substantially all cash equivalents are held in short-term money market accounts at one of the largest financial institutions in the United States. From time to time, our cash account balances are greater than the Federal Deposit Insurance Corporation insurance limit of $250,000 per owner per bank, and during such times, we are exposed to credit loss for amounts in excess of insured limits in the event of non-performance by the financial institution. We do not anticipate non-performance by our financial institution.

 

As of September 30, 2026, and December 31, 2025, our cash balances were made up of the following (in thousands):

 

  

September 30, 2026

  

December 31, 2025

 

BioLargo, Inc. and subsidiaries

 $1,318  $2,826 

Clyra Medical Technologies, Inc.

  215   1,057 

Total

 $1,533  $3,883 

 

- 7 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Accounts Receivable 

 

Accounts receivable are customer obligations that are unconditional. Accounts receivable are presented net of an allowance for expected credit losses, which represents an estimate of amounts that may not be collectible. The Company performs ongoing credit evaluations of its customers and, if necessary, provides an allowance for expected credit losses. A credit loss expense is recorded based on factors including the length of time the receivables are past due, the current business environment, and the Company’s historical experience. Credit loss expense is recorded to general and administrative expenses in the accompanying condensed consolidated statements of operations and comprehensive loss. The Company writes off accounts receivable when it determines a balance is uncollectible and no longer actively pursues collection of the receivable. The Company does not have any off-balance-sheet credit exposure related to customers.  As of September 30, 2026, and December 31, 2025, the allowance for expected credit losses were $712,000 and $700,000, respectively.

 

Allowance for Credit Losses

 

The Company recognizes an expected allowance for credit losses with respect to its accounts receivable. In addition, also at each reporting date, this estimate is updated to reflect any changes in credit risk since the receivable was initially recorded. This estimate is calculated on a pooled basis where similar risk characteristics exist. Accounts receivable are evaluated individually when they do not share similar risk characteristics which could exist in circumstances where amounts are considered at risk or uncollectible. This estimate is adjusted for management's assessment of current conditions, reasonable and supportable forecasts regarding future events, and any other factors deemed relevant by the Company. The Company believes historical loss information is a reasonable starting point in which to calculate the expected allowance for credit losses. The Company writes off receivables when there is information that indicates the customer is facing significant financial difficulty and there is no possibility of recovery. If any recoveries are made from any accounts previously written off, they will be recognized in operations or an offset to credit loss expense in the year of recovery, in accordance with the entity's accounting policy election.

 

On  June 6, 2025, ONM Environmental entered into an amendment to the  June 2021 Preferred Master Manufacturing Agreement with Ikigai Holdings, LLC and Pooph Inc. to allow Pooph Inc. to pay past due amounts of $1,378,141 in royalties and $2,385,468 on product invoices through a weekly payment plan bearing 10% interest and maturing   July 3, 2026 (the “PMMA Amendment”). This amount was recognized on our consolidated balance sheet at  June 30, 2025, as a note receivable. The PMMA Amendment also modified payment and invoicing terms on existing and future product purchase orders, and allowed ONM Environmental to withhold product if the payment terms were not met. On  August 5, 2025, Pooph Inc. delivered a royalty report due for the second quarter of 2025, but did not pay the $463,520 in royalties due. On   August 15, 2025, it failed to make the weekly payment required pursuant to the PMMA Amendment, and has not made a payment since. On  September 19, 2025, Pooph Inc. disclosed that it had been working independently on developing a new formula for Pooph-branded products to replace BioLargo's formula, and that it was terminating the Preferred Master Manufacturing Agreement, citing ONM's refusal to deliver products. On  September 24, 2025, BioLargo and ONM delivered notice to Pooph that its license grant was immediately revoked due to Pooph’s failure to pay royalties, and that it was terminating the License Agreement in its entirety with 150 days’ notice. The notice further advised that Pooph is not allowed to market or sell products that incorporate, use, or are based on, in whole or in part, BioLargo’s patents and proprietary information, including but not limited to know-how, disclosed to Pooph, and that absent reinstatement of the grant of license, Pooph must immediately stop marketing and selling any such products in its possession, custody or control (or sold through market portals or platforms such as Amazon). On  November 11, 2025, BioLargo Inc. and ONM Environmental filed a lawsuit against Pooph Inc. and Ikigai Marketing Works LLC (successor entity to Ikigai Holdings LLC) in the United States District Court for the Central District of California in part to recover the amounts due for product purchases and royalties. (See Note 14, "Legal Proceedings".) 

 

 There were no write-offs of accounts receivable or note receivable during the three and nine months ended September 30, 2026 and 2025. 

 

Credit Concentration

 

We have a limited number of customers that account for significant portions of our revenue. During the three and nine months ended September 30, 2026 and 2025, the following customers accounted for more than 10% of consolidated revenues:

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2026

  

2025

  

2026

  

2025

 

Customer A

  19%  —% 

18

%  —%

Customer B

  16%  —% 

—

%  —%

Customer C

  15%  —% 

14

%  —%

Customer D

  11%  —% 

—

%  —%

Customer E

  —%  —% 

12

%  —%

Customer F

  —%  —% 

11

%  —%

Customer G

  —%  35% 

—

%  64%

 

At September 30, 2026 and  December 31, 2025, the following customers accounted for more than 10% of consolidated accounts receivable:

 

  

September 30, 2026

  

December 31, 2025

 

Customer A

  14%  —%

Customer B

  11%  —%

Customer D

  11%  —%

 

 

- 8 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Inventory

 

Inventories are stated at the lower of cost or net realizable value using the average cost method. There was no allowance for obsolete inventory as of  September 30, 2026, and December 31, 2025.  Inventories consisted of the following (in thousands):

 

  

September 30, 2026

  

December 31, 2025

 

Raw material

 $117  $125 

Finished goods

  205   185 

Total

 $322  $310 

 

Other Non-Current Assets

 

Other non-current assets consisted of (i) security deposits related to our business offices, (ii) three patents acquired on  October 22, 2021, for $34,000, and (iii) interest receivable.

 

  

September 30, 2026

  

December 31, 2025

 

Patents

 $34  $34 

Security deposits

  72   72 

Interest receivable

  10   — 

Total

 $116  $106 

 

Impairment

 

Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  If the sum of the expected future undiscounted cash flows from the use of the asset and its eventual disposition is less than the carrying amount of the asset, then an impairment loss is recognized.  The impairment loss is measured based on the fair value of the asset.  Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operations. 

 

Loss Per Share

 

We report basic and diluted loss per share (“LPS”) for common and common share equivalents. Basic LPS is computed by dividing reported losses by the weighted average shares outstanding. Diluted LPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the three and nine months ended September 30, 2026 and 2025, the denominator in the diluted LPS computation is the same as the denominator for basic LPS due to the Company’s net loss which creates an anti-dilutive effect of the warrants and stock options.  As of  September 30, 2026 the stock options outstanding totaled 84,497,408 and the warrants outstanding totaled 25,666,478.

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, expected credit losses, asset depreciation and amortization, impairment expense, among others.

 

The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our condensed consolidated financial statements.

 

- 9 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Share-Based Compensation Expense

 

We recognize compensation expense for stock option awards on a straight-line basis over the applicable service period of the award, which is the vesting period. Fair value is determined on the grant date. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option pricing model.

 

Share-based payment awards issued to nonemployees in exchange for goods or services are accounted for in accordance with ASC 718. Equity-classified awards are measured at grant-date fair value, and compensation cost is recognized over the period in which the related goods or services are received, generally consistent with the recognition model applied to employee awards and subject to the vesting conditions of the award. The fair value of stock options is estimated using the Black-Scholes option-pricing model.

 

The following methodology and assumptions were used to calculate share-based compensation for the nine months ended September 30, 2026 and 2025:

 

  

2026

  

2025

 
  

Non Plan

  

2024 Plan

  

Non Plan

  

2024 Plan

 

Risk free interest rate

  —%  4.3 - 4.99%  4.23%  3.69 - 4.58%

Expected volatility

  —%  83 - 84%  91%  87 - 91%

Expected dividend yield

  —   —   —   — 

Forfeiture rate

  —   —   —   — 

Life in years

  —   10   10   10 

 

Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. The expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

 

The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future.

 

Warrants

 

Warrants issued with our convertible and non-convertible debt instruments are accounted for under the fair value and relative fair value method. The warrant is first analyzed per its terms as to whether it has derivative features or not. If the warrant is determined to be a derivative and not qualify for equity treatment, then it is measured at fair value using the Black Scholes Option pricing model and recorded as a liability on the condensed consolidated balance sheets. The warrant is re-measured at its then current fair value at each subsequent reporting date (it is “marked-to-market”). If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes Option pricing model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible note. Convertible debt instruments are recorded at fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. The warrant relative fair values are also recorded as a discount to the convertible promissory notes.

 

Non-Cash Transactions

 

We determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received.

 

Revenue Recognition

 

We account for revenue in accordance with ASC 606, “Revenue from Contracts with Customers”. The guidance focuses on the core principle for revenue recognition, which is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve that core principle, the guidance provides that an entity should apply the following steps:

 

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

 

The Company’s products are sold through a contract with the customer and a written purchase order, in which the details of the contract are defined including the transaction price and method of shipment. The only performance obligation is to create and ship the product, and each product has separate pricing. Revenue is recognized at a point in time when the goods are shipped if the agreement is FOB manufacturer, and when goods are delivered if FOB destination. Revenue is recognized with a reduction for sales discounts, as appropriate and negotiated in the customer’s purchase order.

 

Service contracts are performed through a written contract, which specifies the performance obligations and the rate at which the services will be billed, typically by time and materials. Each service is separately negotiated and priced. Revenue is recognized as services are performed and completed, or, for services related to product installations, at the completion of the installation. A few contracts have called for milestone or fixed cost payments, where we invoice an agreed-to amount per month for the life of the contract. In these instances, completed work, billed hourly, is recognized as revenue. If the billing amount is greater or lesser than the completed work, a receivable or payable is created. These accounts are adjusted upon additional billings as the work is completed. To date, there have been no discounts or other financing terms for the contracts.

 

- 10 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

The Company had outstanding contract liability obligations of $615,000 and $280,000 as of September 30, 2026 and December 31, 2025, respectively.  Revenue of $140,000 was recognized in the nine months ended September 30, 2026 from the change in contract liability obligations. Outstanding contract liability obligations are recognized as revenues in accordance with the terms of the governing agreements. In September 2026, Clyra earned a $475,000 contractual payment upon satisfaction of a specified contractual milestone under a distribution agreement granting the customer exclusive rights to distribute certain Clyra products. Because the contractual condition giving rise to the payment had been satisfied as of September 30, 2026, Clyra recorded a $475,000 receivable and a corresponding contract liability. The amount was recorded as a contract liability because the payment relates to performance obligations that had not yet been satisfied as of September 30, 2026. No revenue associated with the payment was recognized during the three or nine months ended September 30, 2026. The contract liability will be recognized as revenue as Clyra satisfies the related performance obligations under the agreement. Our Canadian subsidiary had a grant deposit outstanding at  December 31, 2025, totaling $80,000. These funds were awarded as part of a grant for a particular project that has been delayed. The grant funds were used and recorded against research and development expense. BETI held an investor deposit at  September 30, 2026 and December 31, 2025, totaling $5,000 related to an investor commitment not yet completely fulfilled. Subsequent to September 30, 2026, this deposit was refunded back to the investor.

 

Government Grants

 

We have been awarded multiple research grants from the private and public Canadian research programs. The income we receive directly from grants is recorded as other income. We have been awarded over 90 grants since our first in 2015. Some of the funds from these grants are given directly to third parties (such as the University of Alberta or a third-party research scientist) to support research on our technology. The grants have terms generally ranging between six and eighteen months and support a majority, but not all, of the related research budget costs. This cooperative research allows us to utilize (i) a depth of resources and talent to accomplish highly skilled work, (ii) financial aid to support research and development costs, and (iii) independent and credible validation of our technical claims.

 

The grants typically provide for (i) recurring monthly amounts, (ii) reimbursement of costs for research talent for which we invoice to request payment, and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None of the funds may be used for general administrative expenses or overhead in the United States. These grants have substantially increased our level of research and development activities in Canada. We continue to apply for Canadian government and agency grants to fund research and development activities. Not all of our grant applications have been awarded, and no assurance can be made that any pending grant application, or any future grant applications, will be awarded.

 

Income Taxes

 

The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date.

 

We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation, and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. Management believes there are no unrecognized tax benefits or uncertain tax positions as of September 30, 2026 and December 31, 2025.

 

The Company assessed its earnings history, trends and estimates of future earnings and determined that the deferred tax asset could not be realized as of September 30, 2026 and December 31, 2025. Accordingly, a 100% valuation allowance was recorded against the net deferred tax asset.

 

The Company recognizes interest and penalties on income taxes as a component of income tax expense, should such an expense be realized.

 

Fair Value of Financial Instruments

 

Management believes the carrying amounts of the Company’s financial instruments as of September 30, 2026 and December 31, 2025 approximate their respective fair values because of the short-term nature of these instruments. Such instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and debt obligations. The carrying amount of debt instruments are believed to approximate fair value as the stated interest rates are reflective of the prevailing market rates.

  

Leases

 

At inception of a lease contract, we assess whether the contract is, or contains, a lease. Our assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period of the contract, and (3) whether we have the right to direct the use of the asset during such time period. At inception of a lease, we allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. Leases are classified as either finance leases or operating leases. A lease must be classified as a finance lease if any of the following criteria are met: the lease transfers ownership of the asset by the end of the lease term, the lease contains an option to purchase the asset that is reasonably certain to be exercised, the lease term is for a major part of the remaining useful life of the asset or the present value of the lease payments equals or exceeds substantially all of the fair value of the asset. A lease is classified as an operating lease if it does not meet any of these criteria. We have one lease classified as a finance lease. For all leases at the lease commencement date, a right-of-use asset and a lease liability are recognized. The right-of-use asset represents the right to use the leased asset for the lease term. The lease liability represents the present value of the lease payments under the lease. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, consisting mainly of brokerage commissions, less any lease incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present value of the lease payments, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, management estimates the incremental borrowing rate, which currently is estimated to be 18%. Lease payments included in the measurement of the lease liability comprise the following: the fixed noncancelable lease payments, payments for optional renewal periods where it is reasonably certain the renewal period will be exercised, and payments for early termination options unless it is reasonably certain the lease will not be terminated early. Lease components are included in the measurement of the initial lease liability. Additional payments based on a change in our portion of the operating expenses, including real estate taxes and insurance, are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease liability. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 months or less. The effect of short-term leases on our right-of-use asset and lease liability was not material. 

 

 

- 11 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

As of  September 30, 2026 and December 31, 2025, the operating right-of-use assets totaled $992,000, and $1,028,000, respectively.  As of  September 30, 2026 and December 31, 2025, the operating lease liability totaled $1,042,000 and $1,074,000, respectively, on our condensed consolidated balance sheets related to our operating leases. The finance lease is related to Clyra.  As of  September 30, 2026 and December 31, 2025, the finance right-of-use asset for Clyra totaled $254,000 and $338,000 and the finance lease liability totaled $285,000 and $360,000, respectively, on our condensed consolidated balance sheets. 

 

Equipment and Leasehold Improvements

 

Equipment and leasehold improvements are stated at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, which range from 3 - 10 years. Additions, renewals, and betterments that significantly extend the life of the asset are capitalized. Expenditures for repairs and maintenance are charged to expense as incurred. For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in operations for the period. 

 

  

September 30, 2026

  

December 31, 2025

 

Equipment

 $1,959  $1,724 

Leasehold improvements

  526   526 

Total, at cost

  2,485   2,250 

Less: accumulated depreciation

  (803)  (607)

Total equipment and leasehold improvements, net

 $1,682  $1,643 

 

Noncontrolling Interest

 

A noncontrolling interest is defined as the portion of the equity in an entity not attributable, directly or indirectly, to the primary beneficiary. Noncontrolling interests are required to be presented as a separate component of equity on a condensed consolidated balance sheets. Accordingly, the presentation of net loss is modified to present the loss attributed to controlling and non-controlling interests. The noncontrolling interest on the Company’s condensed consolidated balance sheets represents equity not held by the Company. In accordance with ASC 810-10-20, “Noncontrolling Interests” BioLargo consolidates four non-wholly owned subsidiaries - Clyra Medical, BLEST, BETI and BCPG. Noncontrolling interest of Clyra Medical represents 54% as of September 30, 2026, and 52% as of  December 31, 2025.  Noncontrolling interest of BLEST represents 30% as of September 30, 2026, and  December 31, 2025.  Noncontrolling interest of BETI represents 7% and 5% as of September 30, 2026, and  December 31, 2025.  Noncontrolling interest of BCPG represents 22% as of September 30, 2026.  

   

Recent Accounting Pronouncements

 

In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, as clarified by ASU 2025-01. The guidance requires public business entities to provide additional disclosures regarding specified categories of expenses included in certain income statement captions. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted, and the amendments may be applied prospectively or retrospectively. The Company is evaluating the effect that adoption will have on its disclosures.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements. ASU 2025-11 clarifies interim disclosure requirements and provides a comprehensive list of interim disclosures that are required by GAAP. The ASU also includes a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The standard is effective for interim reporting periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is evaluating the impact of the changes to its condensed consolidated financial statements and existing disclosures.

 

Note 3. Sale of Stock for Cash

 

Lincoln Park Financing

 

During the three months ended March 31, 2026, we sold 984,188 shares of our common stock to Lincoln Park Capital Fund, LLC and received $171,000 in gross and net proceeds pursuant to a purchase agreement dated December 13, 2022, which expired on its own terms in March 2026. No sales of common stock were made to Lincoln Park during the three months ended June 30, 2026, or September 30, 2026.

 

During the three and nine months ended  September 30, 2025 we sold 4,222,467 and 8,299,752 shares of our common stock to Lincoln Park and received $764,000 and $1,587,000 in gross and $749,000 and $1,542,000 net proceeds. 

 

Clearthink Financing

 

On March 20, 2026, we entered into a purchase agreement (the “Purchase Agreement”) with Clearthink Capital Partners, LLC (“Clearthink”), pursuant to which Clearthink committed to purchase up to $10.0 million of the Company’s common stock. Sales of common stock are subject to certain limitations set forth in the Purchase Agreement, and may occur from time to time, at our sole discretion. From and after the April 15, 2026 commence date and until May 1, 2029, unless we are in default of the Purchase Agreement, on any trading day we select, we may, by written notice delivered to Clearthink, direct Clearthink to purchase up to the lesser of (i) $500,000 of our common stock, and (ii) 300% of the daily average shares traded value for the eight trading days prior to the date of the purchase notice, with a minimum of no less than $25,000. At least five business days must elapse between each purchase notice unless the parties mutually agree otherwise. The purchase price per share of Common Stock sold in each such purchase, if any, will be based on prevailing market prices of the common stock immediately preceding the time of sale as computed under the Purchase Agreement, equal to the average of the two lowest daily closing prices of our common stock during the eight trading days preceding the purchase notice. We expect that any proceeds we receive from such sales to Clearthink will be used for working capital and general corporate purposes.  Pursuant to the terms of the Purchase Agreement, we issued Clearthink 500,000 shares of our common stock as payment of the "commitment fee" and we recorded the $85,000 fair value of the shares at $0.17 per share as a financing fee.

 

From the April 15, 2026 commencement date through September 30, 2026, we sold 10,350,000 shares of our common stock to Clearthink and received $1,103,000 in gross and net proceeds.

 

- 12 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Unit Offering

 

During the three months ended March 31, 2026, we sold 555,556 shares of our common stock and received $100,000 gross and net proceeds from one accredited investor.  No sales of common stock were made during the three months ended June 30, 2026 or September 30, 2026. In addition to the shares, we issued the investor a six-month and a five-year warrant to purchase additional shares. (See Note 6, “Warrants Issued in Unit Offering”.) We did not sell shares of our common stock in unit offerings during the nine months ended  September 30, 2025.

 

No financing fee was recorded during the three months ended September 30, 2026.  In the nine months ended September 30, 2026, we recorded a $15,000 financing fee.  In the three and nine months ended September 30, 2025, we recorded a financing fee of $15,000 and $45,000, respectively.

 

Sales of securities in the unit offerings were made in reliance on the exemption from registration contained in Section 4(a)(2) and 4(a)(5) of the Securities Act of 1933 and/or Regulation D promulgated thereunder as not involving a public offering of securities.

 

Note 4. Debt Obligations

 

The following table summarizes our debt obligations outstanding as of September 30, 2026 and December 31, 2025 (in thousands). The table does not include debt obligations of our partially owned subsidiary Clyra Medical (see Note 8, “Debt Obligations of Clyra Medical”).

 

  

September 30, 2026

  

December 31, 2025

 

Current portion of debt:

        

SBA Paycheck Protection Program loan

 $47  $43 

Vehicle loan, current portion

  8   13 

Term loan, current portion

  17   17 

SBA EIDL Loan, matures July 2053, current portion

  10   10 

Total current portion of debt

 $82  $83 
         

Long-term debt:

        

Vehicle loan, matures March 2029

 $19  $29 

Term loan, matures April 2028

  14   22 

SBA EIDL Loan, matures July 2053

  124   131 

Total long-term debt, net of current

 $157  $182 
         

Total

 $239  $265 

 

Interest Expense

 

For the three and nine months ended September 30, 2026, we recognized $317,000 and $790,000, respectively, of interest expense from our debt obligations, inclusive of Clyra Medical debt obligations (see Note 8). For the three and nine months ended September 30, 2025, we recognized $144,000 and $352,000, respectively, of interest expense from our debt obligations, inclusive of Clyra Medical debt obligations.

 

Vehicle loan

 

On February 7, 2023, we entered a loan agreement with Bank of America for the purchase of a commercial vehicle used in operations totaling $80,000, at 5.29% annual interest which matures March 7, 2029. The loan agreement requires monthly payments of $1,000.  As of September 30, 2026, and December 31, 2025, the balance of this loan totaled $27,000 and $42,000, respectively.

 

Term Loan

 

On  April 5, 2025, we entered a term loan agreement with American Express for working capital in the principal amount of $50,000, at 7.98% annual interest, which matures April 10, 2028, and requires monthly payments of $2,000. As of September 30, 2026, and December 31, 2025, the balance of this loan totaled $31,000 and $39,000, respectively.

 

SBA Program Loans

 

On June 3, 2020, ONM Environmental received a $217,000 CARES Act Paycheck Protection Program loan from the U.S. Small Business Administration ("SBA"). On  February 7, 2022, it received notice that the SBA had forgiven $174,000 of the loan. As of September 30, 2026, and December 31, 2025, the outstanding balance on this loan, which is past its maturity date, totaled $47,000 and $43,000, respectively. 

 

In July 2020, ONM Environmental received an Economic Injury Disaster Loan (EIDL) from the SBA in the amount of $150,000. The note has a 3.75% annual interest rate, requires monthly payments of $700, and matures July 2053. As of September 30, 2026, and December 31, 2025, the balance of this loan totaled $134,000 and $141,000, respectively. 

 

- 13 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

 

 

Note 5. Share-Based Compensation

 

Issuance of Common Stock in exchange for Services

 

Payment of Officer Salaries

 

On  September 30, 2026, we issued 1,807,444 shares of our common stock at $0.08 per share in lieu of $154,000 of accrued and unpaid obligations to two officers. On  June 30, 2026, we issued 1,143,753 shares of our common stock at $0.11 per share in lieu of $130,000 of accrued and unpaid obligations to two officers. On  March 31, 2026, we issued 69,444 shares of our common stock at $0.16 per share in lieu of $11,000 of accrued and unpaid obligations to an officer.

 

On  September 30, 2025, we issued 177,235 shares of our common at $0.17 per share in lieu of $30,000 of accrued and unpaid obligations to two officers.  On June 30, 2025, we issued 350,751 shares of our common at $0.21 per share in lieu of $70,000 of accrued and unpaid obligations to two officers. On March 31, 2025, we issued 11,250 shares of our common at $0.28 per share in lieu of $3,000 of accrued and unpaid obligations to an officer.

 

Payment of Consultant and Vendor Fees

 

On  September 30, 2026, we issued 705,000 shares of our common stock at $0.08 per share in lieu of $61,000 of accrued and unpaid obligations to consultants and vendors.  On June 30, 2026, we issued 1,137,681 shares of our common stock at $0.11 per share in lieu of $106,000 of accrued and unpaid obligations to consultants and vendors.  On  March 31, 2026, we issued 212,963 shares of our common at $0.16 per share in lieu of $35,000 of accrued and unpaid obligations to consultants and vendors.

 

During the three months ended  September 30, 2025, we issued 147,059 shares of our common at $0.17 per share in lieu of $25,000 of accrued and unpaid obligations to consultants and vendors. On June 30, 2025, we issued 564,252 shares of our common at $0.21 per share in lieu of $143,000 of accrued and unpaid obligations to consultants and vendors. During the three months ended  March 31, 2025, we issued 209,080 shares of our common at $0.28 per share in lieu of $58,000 of accrued and unpaid obligations to consultants and vendors.

 

All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D promulgated thereunder as not involving a public offering of securities.

   

Stock Option Expense

 

During the three and nine months ended September 30, 2026, we recognized an aggregate $827,000 and $2,248,000, respectively, and during the three and nine months ended September 30, 2025, we recognized an aggregate $844,000 and $1,951,000, respectively, in selling general and administrative expense related to the issuance of stock options. We issued options through our 2024 Equity Incentive Plan, and outside of the plan. Included in these totals is option expense related to issuances by our subsidiary, Clyra Medical, totaling $426,000 and $1,089,000 during the three and nine months ended September 30, 2026. (See Note 8.)

 

2024 Equity Incentive Plan

 

On June 13, 2024, our stockholders adopted the BioLargo 2024 Equity Incentive Plan (“2024 Plan”) as a means of providing our directors, key employees, and consultants additional incentive to provide services. Both stock options and stock grants may be made under this plan for a period of 10 years. It is set to expire on its terms on June 13, 2034. Our Board of Director’s Compensation Committee administers this plan. As plan administrator, the Compensation Committee has sole discretion to set the price of the options. The plan authorizes the following types of awards: (i) incentive and non-qualified stock options, (ii) restricted stock awards, (iii) stock bonus awards, (iv) stock appreciation rights, (v) restricted stock units, and (vi) performance awards. The number of shares available to be issued under the 2024 Plan increases automatically on January 1 of each year by the lesser of (a) 2 million shares, or (b) such number of shares determined by our Board. As of September 30, 2026, 44,000,000 shares are authorized under the plan, and 14,696,683 remain available for grant.

 

Activity for our stock options under the 2024 Plan during the nine months ended September 30, 2026, and 2025, is as follows:

 

  

Options outstanding

  

Weighted average price per share

  

Weighted average remaining life

  

Aggregate intrinsic Value(1)

 

Balance, December 31, 2024

  5,493,920  $0.23         

Granted

  8,985,536  $0.21         

Balance, September 30, 2025

  14,479,456  $0.21         

Unvested

  (4,443,293) $0.21         

Vested Balance, September 30, 2025

  10,036,163  $0.21         
                 

Balance, December 31, 2025

  16,793,014  $0.21         

Granted

  12,597,524  $0.11         

Forfeited

  (87,221) $0.19         

Balance, September 30, 2026

  29,303,317  $0.17   9.0  $— 

Unvested

  (6,526,231) $0.15         

Vested balance, September 30, 2026

  22,777,086  $0.17   8.9  $— 

 

(1) – Aggregate intrinsic value based on closing common stock price of $0.08 at September 30, 2026.

 

- 14 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

The options granted to purchase 12,597,524 shares during the nine months ended September 30, 2026 with an aggregate fair value of $1,145,000 were issued to board of directors, employees and consultants: (i) we issued options to purchase 2,239,442 shares of our common stock to members of our board of directors for services performed, in lieu of cash; the fair value of these options totaled $200,000; (ii) we issued options to purchase 4,088,987 shares of our common stock to employees as part of employee retention plans; the fair value of employee retention plan options totaled $365,000 and vest over time or based on performance metrics; (iii) we issued options to purchase 5,969,095 shares of our common stock to consultants in lieu of cash for expiring options and for services performed; the fair value of these options totaled $534,000 and (iv) we issued options to purchase 300,000 shares of our common stock to our Chief Financial Officer with a fair value of $46,000 for expiring options.

 

As of September 30, 2026, there remains $842,000 of stock option expense to be expensed over the next four years.

 

The options granted to purchase 8,985,536 shares during the nine months ended September 30, 2025 with an aggregate fair value of $1,577,000 were issued to board of directors, employees and consultants: (i) we issued options to purchase 1,241,688 shares of our common stock to members of our board of directors for services performed, in lieu of cash; the fair value of these options totaled $235,000; (ii) we issued options to purchase 4,907,811 shares of our common stock to employees as part of employee retention plans; the fair value of employee retention plan options totaled $793,000 and vest over time or based on performance metrics; (iii) we issued options to purchase 2,536,037 shares of our common stock to consultants in lieu of cash for expiring options and for services performed; the fair value of these options totaled $482,000 and (iv) we issued options to purchase 300,000 shares of our common stock to our Chief Financial Officer with a fair value of $67,000 for expiring options. All stock option expense is recorded on our condensed consolidated statement of operations as selling, general and administrative expense.

 

Extension of Agreement with Chief Financial Officer

 

On  January 31, 2026, the Engagement Agreement with our Chief Financial Officer Charles K. Dargan, II automatically extended for a one-year period to expire  January 31, 2027 (the “2026-27 Term”). As the sole compensation for the 2026-27 Term, and in accordance with his contract, Mr. Dargan was issued an option (“Option”) to purchase 300,000 shares of the Company’s common stock. The Option vests over the period of the extended term in monthly installments of 25,000 shares, so long as the agreement is in full force and effect. The Option is exercisable at $0.18 per share, the closing price of BioLargo’s common stock on the last trading day of January 2026, expires ten years from the grant date, and was issued pursuant to the Company’s 2024 Equity Incentive Plan.

 

On  January 31, 2025, the Engagement Agreement with our Chief Financial Officer Charles K. Dargan, II automatically extended for a one-year period to expire January 31, 2026 (the “2025-26 Term”). As the sole compensation for the 2025-26 Term, Mr. Dargan was issued an option (“Option”) to purchase 300,000 shares of the Company’s common stock. The Option vests over the period of the extended term in monthly installments of 25,000 shares, so long as the agreement is in full force and effect. The Option is exercisable at $0.25 per share, the closing price of BioLargo’s common stock on the last trading day of January 2025, expires ten years from the grant date, and was issued pursuant to the Company’s 2024 Equity Incentive Plan.

 

2018 Equity Incentive Plan

 

On June 22, 2018, our stockholders adopted the BioLargo 2018 Equity Incentive Plan (“2018 Plan”) as a means of providing our directors, key employees, and consultants additional incentive to provide services. Both stock options and stock grants may be made under this plan for a period of 10 years. It is set to expire on its terms on June 22, 2028. Our Board of Director’s Compensation Committee administers this plan.  As of June 30, 2024, the 2018 Plan closed to further stock option grants.  The 2018 Plan closed with 9,343,614 shares unissued.

 

Activity for our stock options under the 2018 Plan during the nine months ended September 30, 2026, and 2025, is as follows:

 

  

Options outstanding

  

Weighted average price per share

  

Weighted average remaining life

  

Aggregate intrinsic Value(1)

 

Balance, December 31, 2024

  42,171,386  $0.19         

Exercised

  (566,951) $0.16         

Balance, September 30, 2025

  41,604,435  $0.19         

Unvested

  (1,946,350) $0.23         

Vested Balance, September 30, 2025

  39,658,085  $0.19         
                 

Balance, December 31, 2025

  41,604,435  $0.19         

Exercised

  —  $—         

Balance, September 30, 2026

  41,604,435  $0.19   5.1  $— 

Unvested

  (1,139,555) $0.23         

Vested balance, September 30, 2026

  40,464,880  $0.19   5.0  $— 

 

(1) – Aggregate intrinsic value based on closing common stock price of $0.08 at September 30, 2026

 

During the nine months ended September 30, 2025, an option holder elected to exercise 566,951 options using the cashless exercise option in exchange for 265,800 shares of our common stock.

 

As of September 30, 2026, there remains $178,000 of stock option expense to be expensed over the next two years.

 

- 15 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

2007 Equity Incentive Plan

 

On September 7, 2007, and as amended April 29, 2011, the BioLargo, Inc. 2007 Equity Incentive Plan (“2007 Plan”) was adopted as a means of providing our directors, key employees and consultants additional incentive to provide services. Both stock options and stock grants may be made under this plan for a period of 10 years, which expired on September 7, 2017. The Board’s Compensation Committee administers this plan. As plan administrator, the Compensation Committee has sole discretion to set the price of the options. As of September 2017, the Plan was closed to further stock option grants.

 

Activity for our stock options under the 2007 Plan for the nine months ended September 30, 2026 and 2025 is as follows:

 

  

Options Outstanding

  

Weighted average price per share

  

Weighted average remaining life

  

Aggregate intrinsic Value(1)

 

Balance, December 31, 2024

  1,157,500  $0.53         

Expired

  (777,500) $0.42         

Balance, September 30, 2025

  380,000  $0.61         
                 

Balance, December 31, 2025

  380,000  $0.63         

Expired

  (40,000) $0.48         

Balance, September 30, 2026

  340,000  $0.63   0.4  $— 

 

(1) – Aggregate intrinsic value based on closing common stock price of $0.08 at September 30, 2026.

 

Non-Plan Options

 

Activity of our non-plan stock options issued for the nine months ended September 30, 2026 and 2025 is as follows:

 

  

Non-plan Options outstanding

  

Weighted average price per share

  

Weighted average remaining life

  

Aggregate intrinsic Value(1)

 

Balance, December 31, 2024

  15,687,642  $0.40         

Granted

  32,143  $0.28         

Expired

  (1,793,434) $0.39         

Balance, September 30, 2025

  13,926,351  $0.40         

Unvested

  (218,750) $0.44         

Vested Balance, September 30, 2025

  13,707,601  $0.39         
                 

Balance, December 31, 2025

  14,039,129  $0.39         

Expired

  (789,473) $0.46         

Balance, September 30, 2026

  13,249,656  $0.38   1.2  $- 

Unvested

  (156,250) $0.18         

Vested balance, September 30, 2026

  13,093,406  $0.38   1.2  $- 

 

(1) – Aggregate intrinsic value based on closing common stock price of $0.08 at September 30, 2026.

 

There were no non-plan options issued during the nine months ended September 30, 2026. 

 

During the nine months ended September 30, 2025, we issued options to purchase an aggregate 32,143 shares of our common stock at $0.28 per share to vendors for fees for services.  The fair value of the options issued totaled an aggregate $8,000 and is recorded in our selling, general and administrative expense.  As of September 30, 2025, there remains $55,000 of stock option expense to be expensed over the next one year.

 

- 16 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
 

Note 6. Warrants

 

We have certain warrants outstanding to purchase our common stock, at various prices, for the nine months ended September 30, 2026 and 2025 is as follows:

 

  

Warrants outstanding

  

Weighted average price per share

  

Weighted average remaining life

  

Aggregate intrinsic value(1)

 

Balance, December 31, 2024

  31,615,616  $0.29         

Expired

  (2,634,698) $0.22         

Vested Balance, September 30, 2025

  28,980,918  $0.29         
                 

Balance, December 31, 2025

  31,244,078  $0.29         

Issued

  1,198,832  $0.24         

Expired

  (6,776,432) $0.22         

Vested Balance, September 30, 2026

  25,666,478  $0.31   1.3  $— 

 

(1) – Aggregate intrinsic value based on closing common stock price of $0.08 at September 30, 2026.

 

Warrants issued in Unit Offerings

 

During the nine months ended September 30, 2026, we issued six-month stock purchase warrants to purchase an aggregate 599,416 shares of our common stock at $0.22 per share, and five-year stock purchase warrants to purchase an aggregate 599,416 shares of our common stock at $0.27 per share, in conjunction with the sale of stock to investors in our Unit Offerings (see Note 3). The relative fair value of the warrant component of the units sold to investors totaled $58,000. The Black-Scholes model was used to calculate relative fair value, further discounted by the beneficial conversion feature and the value of the common stock component.

 

We did not issue any warrants in conjunction with unit offerings in the nine months ended September 30, 2025.

 

Warrant Fair Value

 

We use the Black-Scholes option pricing model to determine the relative fair value of warrants issued in conjunction with debt instruments, common stock, and for services. With respect to debt instruments, relative fair value is amortized over the life of the debt's effective-interest period. The principal assumptions we used in applying the Black-Scholes model were as follows:

 

  

2026

  

2025

 

Risk free interest rate

  3.64 - 3.77%  3.67 - 3.73%

Expected volatility

  62 - 66%  72 - 73%

Expected dividend yield

  —   — 

Forfeiture rate

  —   — 

Expected life in years

  .5 - 5   .5 - 5 

 

The risk-free interest rate is based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant.

 

- 17 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Note 7. Accounts Payable and Accrued Expenses

 

As of September 30, 2026, accounts payable and accrued expenses included the following (in thousands):

 

Category

 

BioLargo

  

ONM

  

BLEST

  

BioLargo Canada

  

BETI

  

BEST

  

Intercompany amounts

  

Totals

 

Accounts payable

 $523  $307  $27  $154  $21  $—  $(3) $1,029 

Accrued payroll

  38   106   242   -   —   -   —   386 

Total

                             $1,415 

 

As of December 31, 2025, accounts payable and accrued expenses included the following (in thousands):

 

Category

 

BioLargo

  

ONM

  

BLEST

  

BioLargo Canada

  

BETI

  

BEST

  

Intercompany amounts

  

Totals

 

Accounts payable

 $588  $305  $—  $100   43  $—  $(24) $1,012 

Accrued payroll

  10   85   73   22   —   9   —   199 

Total

                             $1,211 

 

See Note 8, “Accounts Payable and Accrued Expenses”, for the accounts payable and accrued expenses of Clyra Medical.

 

Note 8. Noncontrolling Interest – Clyra Medical

 

As discussed in Note 2 above, we consolidate the operations of our partially owned subsidiary Clyra Medical.

 

Debt Obligations of Clyra Medical

 

Secured Promissory Notes

 

During fiscal year 2024, Clyra issued promissory notes in the aggregate amount of $1,064,000, the funds of which were used to purchase and secured by equipment for at-scale production of its wound irrigation solution products. Of this total, $200,000 was issued to BioLargo and this eliminates during consolidation of intercompany transactions. The notes bear interest at the rate of 15% per annum, were scheduled to mature October 31, 2026, and require interest-only payments until maturity. Each investor received a warrant to purchase the number of Clyra common shares equal to the face amount of the note divided by six, at an exercise price of $6.00 per share, expiring  October 31, 2029. Warrants to purchase an aggregate 231,666 shares of Clyra common stock were issued. During fiscal year 2025, Clyra issued secured promissory notes in the aggregate amount of $436,000, the funds of which were used to purchase equipment for at-scale manufacture of its products. The notes bear interest at the rate of 15% per annum, were scheduled to mature on  December 31, 2026, require interest-only payments until maturity, and  may be pre-paid at any time. Each investor received a warrant to purchase the number of Clyra common shares equal to the face amount of the note divided by six, at an exercise price of $6.00 per share, expiring  October 31, 2029.  Warrants to purchase an aggregate 72,667 shares of Clyra common stock were issued. The fair value of the warrants totaled $99,000 and is recorded as a debt discount, which is amortized as interest expense over the term of the secured promissory note.  As of  September 30, 2026, and December 31, 2025, the outstanding balance totaled $1,500,000, of which $200,000 is owed to BioLargo Inc. and eliminated in consolidation. Subsequent to September 30, 2026, the maturity dates of $1,260,000 of these notes were extended to December 31, 2028 (see Note 15).

 

Promissory Notes (Guaranteed by BioLargo Inc.)

 

During the three months ended September 30, 2026, Clyra issued promissory notes in the aggregate amount of $675,000 maturing July 31, 2029. The notes bear interest at the rate of 15% per annum and require monthly cash interest payments in the aggregate amount of $8,500. BioLargo Inc. guaranteed payment of the notes. Each investor received a warrant to purchase an aggregate number of Clyra common shares equal to the face amount of the note divided by 7.5, at an exercise price of $7.50 per share, expiring July 31, 2031. Warrants to purchase an aggregate 90,001 shares of Clyra common stock were issued. The fair value of these warrants issued totaled $84,000 and is recorded as a debt discount and will be amortized to interest expense over the term of the guaranteed note offering. See also Note 15.

 

During the six months ended June 30, 2026, Clyra issued promissory notes in the aggregate amount of $3,391,500 maturing February 28, 2029. The notes bear interest at the rate of 15% per annum and require monthly cash interest payments in the aggregate amount of $42,000. BioLargo Inc. guaranteed payment of the notes. Each investor received a warrant to purchase an aggregate number of Clyra common shares equal to the face amount of the note divided by 7.5, divided by two, at an exercise price of $7.50 per share, expiring February 28, 2031. Warrants to purchase an aggregate 316,345 shares of Clyra common stock were issued. The fair value of these warrants issued totaled $353,000 and is recorded as a debt discount and will be amortized to interest expense over the term of the guaranteed note offering. 

 

During fiscal year 2025, Clyra issued promissory notes in the aggregate amount of $575,000 maturing July 15, 2027. The notes bear interest at the rate of 15% per annum and require monthly cash payments in the aggregate amount of $7,000. BioLargo Inc. guaranteed payment of the notes. Each investor received a warrant to purchase an aggregate number of Clyra common shares equal to the face amount of the note divided by six point five, at an exercise price of $6.50 per share, expiring  July 15, 2028. Warrants to purchase an aggregate 88,462 shares of Clyra common stock were issued. The fair value of these warrants issued totaled $80,000 and is recorded as a debt discount and will be amortized to interest expense over the term of the guaranteed promissory notes.  

 

As of  September 30, 2026, and December 31, 2025, the aggregate outstanding amounts due on these promissory notes totaled $4,641,500 and $575,000, respectively. As of  September 30, 2026, and December 31, 2025, the aggregate outstanding debt discount totaled $475,000 and $195,000, respectively.  

 

Line of Credit

 

On June 30, 2020, Clyra Medical entered into a Revolving Line of Credit Agreement whereby Vernal Bay Capital Group, LLC ("Vernal") committed to provide a $1,000,000 inventory line of credit. Since inception, Clyra Medical received $260,000 in draws. As of  December 31, 2025 the balance outstanding on this line of credit totaled $134,000.  During the nine months ended September 30, 2026, this line of credit was paid in full.

 

- 18 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Equity Transactions

 

As of September 30, 2026, and December 31, 2025, Clyra had 11,878,545 and 11,375,860 shares issued and outstanding, of which 746,418 and 330,000 were Series A and Series B Preferred shares, respectively.  As of September 30, 2026, and December 31, 2025, of the total outstanding Clyra shares, BioLargo owned 5,305,156, common shares and 165,765 Series A Preferred shares. 

 

Sales of Series A Preferred Stock

 

In an offering that closed in October 2023, Clyra sold 746,418 shares of its Series A Preferred Stock, and in exchange received $1,800,000 in gross and net proceeds. Purchasers of the Series A Preferred Stock also received a 3-year warrant to purchase the same number of additional shares of common stock for $3.72 per share. The fair value of the warrants issued totaled $524,000. Shares of Series A Preferred Stock earn a dividend of 15% each year, compounding annually; the company is under no obligation to pay such dividends in cash, and such dividends automatically convert to common stock upon conversion of the Series A Preferred Stock to common stock. Each share of Series A Preferred Stock can be converted by the holder at any time for one share of common stock and automatically convert upon the completion of a public offering of shares in which at least $5,000,000 of gross proceeds is received by the company. Accrued dividends  may be converted to common stock at a conversion rate of $3.10 per share.  As of September 30, 2026 and December 31, 2025, the Series A Preferred Stock accrued and unpaid dividend totaled $1,197,000 and $937,000, respectively. Each investor also entered into an agreement with BioLargo whereby the investor  may exchange some or all of its Series A Preferred Stock into shares of BioLargo common stock during the period beginning  January 1, 2025, and ended on  June 30, 2026. As of September 30, 2026, no investors have elected to convert.

 

Sales of Series B Preferred Stock

 

In an offering that closed in  October 2025, Clyra sold 330,000 shares of its Series B Preferred Stock, and in exchange received $2,145,000 in gross and net proceeds. Purchasers of the Series B Preferred Stock also received warrants to purchase an aggregate 165,000 shares of common stock for $7.50 per share, expiring three years from the grant date. The fair value of the warrants issued totaled $94,000.

  

Sales of Common Stock

 

There were no sales of common stock by Clyra during the nine months ended September 30, 2026. 

 

During the nine months ended September 30, 2025 Clyra sold 49,167 shares of its common stock, and issued 24,584 warrants to purchase shares of its common stock at $7.50 per share, expiring  February 28, 2027, from five accredited investors. In exchange, it received $295,000 in gross proceeds.  The relative fair value of these warrants totaled $38,000.

 

Common Stock issued for services

 

During the nine months ended  September 30, 2026 Clyra issued 2,685 shares of common stock to a vendor for services performed in lieu of cash totaling $17,000. 

 

During the nine months ended September 30, 2025 Clyra issued 31,391 shares of its common stock to vendors for services performed in lieu of cash totaling $60,000 and issued a warrant to purchase 7,849 shares of its common stock at $6.00 per share, expiring 5 years from the grant date. The relative fair value of these warrants totaled $6,000.

 

Clyra Stock Options

 

  

Clyra Options Outstanding

  Weighted average price per share  

Weighted average remaining life

 

Balance, December 31, 2024

  1,976,863  $1.00     

Granted

  103,774  $4.50     

Balance, September 30, 2025

  2,080,637  $1.17     

Unvested

  (176,667) $0.69     

Vested Balance, September 30, 2025

  1,903,970  $1.22     
             

Balance, December 31, 2025

  3,013,692  $2.17     

Granted

  428,773  $2.41     

Exercised

  (500,000) $0.01     

Balance, September 30, 2026

  2,942,465  $2.71   6.9 

Unvested

  (664,962) $4.33     

Vested Balance, September 30, 2026

  2,277,503  $2.23   6.2 

 

Clyra issues options to its employees and consultants in lieu of compensation owed on a regular basis.  The fair value of the options issued totaled $1,089,000 in the nine months ended September 30, 2026, and $599,000 in the nine months ended September 30, 2025. The Black-Scholes model is used to calculate the initial fair value, during the nine months ended September 30, 2026 and 2025, we used a stock price on the date of grant of $4.50 per share. Because Clyra is a private company with no secondary market for its common stock, the resulting fair value was discounted by 30%.

 

As of September 30, 2026, there remains $1,148,000 of stock option expense to be expensed over the next two years.

 

  

September 30, 2026

  

September 30, 2025

 

Risk free interest rate

  4.20 - 4.75%  4.27 - 4.45%

Expected volatility

  23 - 52%  21 - 43%

Expected dividend yield

  —   — 

Forfeiture rate

  —   — 

Expected life in years

  10   10 

 

- 19 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

Clyra Warrants

 

  

Clyra Warrants Outstanding

  

Weighted average price per share

  

Weighted average remaining life

 

Balance, December 31, 2024

  1,183,182  $4.84     

Granted

  747,991  $7.15     

Expired

  (241,073) $6.55     

Vested Balance, September 30, 2025

  1,690,100  $5.38     
             

Balance, December 31, 2025

  1,702,496  $5.39     

Granted

  351,345  $10.73     

Expired

  (474,346) $3.72     

Vested Balance, September 30, 2026

  1,579,495  $7.15   1.8 

 

Accounts Payable and Accrued Expenses

 

At September 30, 2026, and December 31, 2025, Clyra had the following accounts payable and accrued expenses (in thousands):

 

Category

 

2026

  

2025

 

Accounts payable

 $814  $634 

Accrued interest

  15   — 

Accrued dividend

  1,197   937 

Accrued payroll

  96   21 

Total

 $2,122  $1,592 

 

Sale and leaseback of equipment 

 

On  December 4, 2024, Clyra entered into an agreement whereby it sold and leased back certain equipment to be used in the manufacturing of its wound irrigation solution. Clyra received $350,000 cash and a secured promissory note in the principal amount of $82,000 which bears interest at 15%, requires interest be paid monthly, and the principal balance due on  December 4, 2028. The obligations of the note are secured by the equipment pursuant to a security agreement. Concurrently, Clyra leased the equipment for a 49-month term.  The remaining lease payments total $337,000. 

 

On September 10, 2026, Clyra entered into an agreement whereby it sold and leased back certain equipment to be used in the manufacturing of its wound irrigation solution. Clyra received $232,500 cash and a secured promissory note in the principal amount of $542,500 which bears interest at 4%, requires bi-weekly payments of $3,000, and matures September 30, 2036. The obligations of the note are secured by the equipment pursuant to a security agreement. The lease is for a period of ten years, requires payments of $5,500 per month for 24 months, $7,500 for 36 months, and $8,200 for 60 months. At the end of the lease term, Clyra has the option to purchase the equipment for $80,000. The remaining lease payments total $894,000. Each investor received a warrant to purchase 17,500 shares of Clyra common stock, at an exercise price of $7.50 per share, expiring March 4, 2031.  The fair value of these warrants issued totaled $54,000 and is recorded as a debt discount and will be amortized to interest expense over the term of the financing note payable. The Black-Scholes model is used to calculate the initial fair value of the warrants issued as part of the Clyra Medical debt obligations, we used a stock price on the date of grant of $6.00 per share, volatility ranging between 35 - 52%. Because Clyra is a private company with no secondary market for its common stock, the resulting fair value was discounted by 30%.

 

The transaction did not qualify for sale-leaseback accounting under ASC 842 and, accordingly, was accounted for as a financing arrangement. As a result, the related contractual payments are not included in the minimum lease payment table below. Future minimum lease payments under non-cancellable leases, reconciled to our discounted finance lease liabilities are as follows (in thousands):

Year ending

    

December 31, 2026

 $37 

December 31, 2027

  150 

December 31, 2028

  150 

Total minimum lease payments

 $337 

Less imputed interest

  (52)

Total finance lease liabilities

 $285 

 

- 20 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
 

Note 9. BioLargo Engineering, Science and Technologies, LLC

 

In  September 2017, we commenced a full-service environmental engineering firm and formed a Tennessee entity named BioLargo Engineering, Science & Technologies, LLC (“BLEST”). In conjunction with the start of this subsidiary, we entered into an office lease in the Knoxville, Tennessee area, and entered into employment agreements with six scientists and engineers. BLEST was capitalized with two classes of membership units: Class A, 100% owned by BioLargo, and Class B, held by management of BLEST, and which initially had no “profit interest,” as that term is defined in Tennessee law. Class B members were also granted options to purchase up to an aggregate 1,750,000 shares of BioLargo common stock. The profit interest and option shares are subject to a five-year vesting schedule tied to the performance of the subsidiary. As of September 30, 2026 and December 31, 2025, Class B members have earned a 30% profit interest. 

 

 

Note 10. BioLargo Energy Technologies, Inc.

 

BioLargo Energy Technologies, Inc. (“BETI”) was formed for the purpose of commercializing a proprietary liquid sodium battery technology. BioLargo purchased 9,000,000 shares of its common stock upon its formation and was initially its sole stockholder.

 

During the nine months ended September 30, 2026, BETI sold 131,622 shares of its common stock at $3.70 per share to eight accredited investors and received $487,000 in gross and net proceeds. No sales were made during the three months ended September 30, 2026. During the nine months ended September 30, 2025, BETI sold 27,017 shares of its common stock at $3.70 per share to one accredited investor and received $100,000 in gross and net proceeds.  

 

During the nine months ended September 30, 2025, an investor elected to exchange 25,000 shares of BETI common stock into 153,261 shares of BioLargo common stock. In exchange for the issuance of the shares of BioLargo common stock, BioLargo received and now holds the 25,000 exchanged shares of BETI common stock.

 

As of September 30, 2026, and December 31, 2025, BETI had 9,880,361 and 9,605,826 issued and outstanding shares.  During the three months ended September 30, 2026, BioLargo exchanged intercompany payables totaling $525,000 for 141,892 shares of BETI common stock. As of September 30, 2026, and December 31, 2025, BioLargo holds 9,236,892 and 9,095,000 shares of BETI common stock.

 

Note 11. BioLargo CPG LLC

 

BioLargo CPG LLC (“BCPG”) was formed to commercialize household consumer products based on BioLargo's technologies. Company members include management and key service providers. As of September 30, 2026, BioLargo owns 78%.

 

During the nine months ended September 30, 2026, BCPG issued 5,482 membership shares at $5.00 per share to a vendor in lieu of accrued and unpaid services totaling $27,000.  

 

 

Note 12. Business Segment Information

 

The Company’s chief operating decision maker, or “CODM,” is its Chief Executive Officer. The CODM evaluates the performance of the Company’s operating segments and makes resource-allocation decisions primarily using segment operating income or loss. Segment operating income or loss is calculated as segment revenue, less cost of revenues, selling, general and administrative expenses, research and development expenses, and depreciation and amortization attributable to the segment. The measure excludes certain corporate expenses, interest income and expense, finance fees, income taxes, and other items that are not included in the CODM’s assessment of segment operating performance.

 

BioLargo has seven operating business segments, plus its corporate entity which is responsible for general corporate operations, including administrative functions, finance, human resources, marketing, legal, etc. The operational business segments are:

 

 

1.

ONM Environmental -- which sells odor and volatile organic control products and services, located in Westminster, California;

 

2.

Clyra Medical Technologies (“Clyra Medical”) -- which develops and sells medical products based on our technologies, located in Tampa, Florida;

 

3.

BioLargo Engineering (BLEST) -- which provides professional engineering services on a time and materials basis for outside clients and supports our internal operations as needed, located in Oak Ridge, Tennessee;

 

4.

BioLargo Canada, Inc. (“BioLargo Canada”) – the main hub of our scientists researching and developing our technologies, operating out of the University of Alberta, Edmonton, Canada;

 

5.

BioLargo Energy Technologies, Inc. (“BETI”) – which is developing our proprietary battery technology; 

 

6.

BioLargo Equipment Solutions & Technologies, Inc. (“BEST”) – which manages the sales and distribution of our water treatment products and related services; and

 7.BioLargo CPG LLC ("BCPG") - founded in 2026 to commercialize household consumer products based on our technologies.

 

Other than ONM Environmental, none of our operating business units have operated at a profit, and therefore have required additional cash to meet its monthly expenses, funded through sales of debt or equity, research grants, and tax credits. BETI and Clyra Medical have also been funded by third party investors who invest directly in exchange for equity ownership in that entity.

 

- 21 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

The segment information for the three and nine months ended September 30, 2026, and 2025, is as follows (in thousands):

 

  

Three Months Ended September 30,

  

Nine Months Ended September 30,

 
  

2026

  

2025

  

2026

  

2025

 

Revenue

                

ONM Environmental

 $523  $776  $1,419  $5,583 

BioLargo corporate

  -   —   9   — 

BLEST

  793   450   2,679   2,080 

Clyra Medical

  —   —   154   — 

BioLargo Canada

  6   37   132   46 

Intersegment revenue

  (232)  (160)  (941)  (561)

Total

 $1,090  $1,103  $3,452  $7,148 
                 

Stock option expense

                

BioLargo corporate

 $401  $651  $1,159  $1,352 

Clyra Medical

  426   193   1,089   599 

Total

 $827  $844  $2,248  $1,951 
                 

Depreciation expense

                

BioLargo corporate

 $(9) $(9) $(28) $(28)

ONM Environmental

  (9)  (11)  (33)  (34)

BLEST

  (9)  (9)  (26)  (37)

Clyra Medical

  (99)  (3)  (103)  (7)

BETI

  (2)  (2)  (6)  (6)

Total

 $(128) $(34) $(196) $(112)
                 

Research and development expense

                

BioLargo corporate

 $(239) $(175) $(823) $(642)

BLEST

  (231)  (222)  (694)  (541)

BETI

  (146)  (47)  (444)  (161)

BioLargo Canada

  11   (100)  (168)  (356)

Clyra Medical

  (432)  (231)  (1,563)  (795)

BCPG

  (10)  —   (50)  — 

Intersegment R&D

  237   160   937   561 

Total

 $(810) $(615) $(2,805) $(1,934)
                 

Operating income (loss)

                

BioLargo corporate

 $(848) $(1,172) $(2,200) $(3,034)

ONM Environmental

  (45)  (3,807)  (241)  (2,026)

BLEST

  (306)  (403)  (727)  (763)

BETI

  (332)  (128)  (1,026)  (346)

BEST

  (87)  (83)  (252)  (208)

BioLargo Canada

  (27)  (104)  (245)  (404)

BCPG

  (34)  —   (94)  — 

Clyra Medical

  (1,843)  (1,483)  (5,669)  (4,063)

Total

 $(3,522)  (7,180) $(10,454) $(10,844)
                 

Interest income (expense)

                

BioLargo corporate

 $1  $3  $65  $9 

ONM Environmental

  1   44   (2)  90 

    BLEST

  —   14   —   15 

Clyra Medical

  (304)  (125)  (753)  (323)

Total

 $(302) $(64) $(690) $(209)
                 

Net income (loss)

                

BioLargo corporate

 $(847) $(1,169) $(2,220) $(3,025)

ONM Environmental

  (44)  (3,764)  (243)  (1,936)

BLEST

  (306)  (388)  (727)  (748)

BETI

  (332)  (128)  (1,026)  (346)

BEST

  (87)  (83)  (252)  (208)

BioLargo Canada

  (27)  (104)  (246)  (399)

BCPG

  (34)  —   (94)  — 

Clyra Medical

  (2,147)  (1,608)  (6,421)  (4,385)

Total

 $(3,824) $(7,244) $(11,229) $(11,047)

 

- 22 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 

As of September 30, 2026

 

BioLargo

  

ONM

  

CLYRA

  

BLEST

  

BETI

  

BioLargo Canada

  

BCPG

  

Elimination

  

Total

 

Tangible assets

 $557  $1,402  $2,841  $1,207  $35  $112  $17  $(203) $5,968 

Operating lease right-of use

  258   —   155   579   —   —   —   —   992 

Finance lease right-of-use

  —   —   254   —   —   —   —   —   254 

Total

 $815  $1,402  $3,250  $1,786  $35  $112  $17  $(203) $7,214 

 

As of December 31, 2025

 

BioLargo

  

ONM

  

CLYRA

  

BLEST

  

BETI

  

BioLargo Canada

  

Elimination

  

Total

 

Tangible assets

 $694  $2,331  $2,650  $1,169  $4  $321  $(224) $6,945 

Operating lease right-of use

  238   —   175   615   —   —   —   1,028 

Finance lease right-of-use

  —   —   338   —   —   —   —   338 

Total

 $932  $2,331  $3,163  $1,784  $4  $321  $(224) $8,311 

 

 

Note 13. Leases

 

Office Leases

 

We have long-term operating leases for office, industrial and laboratory space in Westminster, California, Oak Ridge, Tennessee, and Alberta, Canada. Payments made under operating leases are charged to the condensed consolidated statement of operations and comprehensive loss on a straight-line basis over the term of the operating lease agreement. Short-term leases less than one-year are not included in our analysis. For the three and nine months ended September 30, 2026, rental expense totaled $97,000 and $307,000 and for the three and nine months ended September 30, 2025, rental expense totaled $97,000 and $164,000.  The lease of our Westminster facility expires  August 2027.  The lease for Clyra Medical expires August 2030.  The lease of our Canadian facility is less than one year. None of our leases have additional terms related to the payments or mechanics of the lease. The leases have no additional payment terms such as common area maintenance payments, tax sharing payments or other allocable expenses. Likewise, the leases do not contain other terms and conditions of use, such as variable lease payments, residual value guaranties or other restrictive financial terms. Since there is no explicit interest rate in our leases, management used its incremental borrowing rate, which is estimated to be 18% to determine lease liability.  As of September 30, 2026, the weighted average remaining lease term for our operating leases was five years and the total remaining operating lease payments were $1,552,000. 

 

Future minimum lease payments under noncancelable leases, reconciled to the Company’s discounted operating lease liabilities are as follows:

 

  

BioLargo

             

Year ending

 

Corp / ONM

  

CLYRA

  

BLEST

  

Total

 

December 31, 2026

 $41  $15  $41  $97 

December 31, 2027

  166   59   163   388 

December 31, 2028

  99   60   166   325 

December 31, 2029

  —   61   170   231 

December 31, 2030

  —   27   173   200 

Thereafter

  —   —   311   311 

Total minimum lease payments

 $306  $222  $1,024  $1,552 

Less imputed interest

  (47)  (56)  (407)  (510)

Total operating lease liabilities

 $259  $166  $617  $1,042 

  

 

Note 14.  Legal Proceedings

 

ONM Environmental, Inc. is the defendant in a lawsuit filed by Pooph Inc. in the Orange County, California Superior Court on September 11, 2025. The lawsuit alleges three causes of action, for Breach of Contract, Breach of Implied Covenant of Good Faith and Fair Dealing, and Declaratory judgment, and seeks an unspecified amount of damages, allegedly arising from ONM’s manufacture of pet odor-control products sold by Pooph Inc. 

 

BioLargo, Inc., BioLargo Life Technologies, Inc., and ONM Environmental, Inc., filed a lawsuit against Pooph, Inc. and Ikigai Marketing Works, LLC in the United States District Court, Central District of California, on November 11, 2025, for patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices and constructive fraud, seeking to recover, amongst other damages, the defendants’ failure to pay for product purchases and license royalties in the aggregate amount of $3,821,401. See Note 2, Allowance for Credit Losses, above.

 

While the outcomes of the lawsuits are uncertain, management believes that the resolutions of these proceedings will not have a material adverse effect on the Company's financial position, results of operations, or cash flows. However, adverse outcomes could materially impact future financial results.

 

- 23 -

BIOLARGO, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
 
Note 15. Subsequent Events

 

The Company has evaluated subsequent events through the date of the filing of this Quarterly Report and reports the following.

 

Stock Issuances

 

Subsequent to September 30, 2026, we have sold 3,600,000 shares of our common stock to Clearthink (see Note 3) and received $254,000 in gross proceeds. 

 

Clyra Medical Financing Activities

 

Subsequent to September 30, 2026, Clyra issued promissory notes in the aggregate amount of $768,000 to seven accredited investors. The notes bear interest at the rate of 15% per annum, mature  July 31, 2029, and are guaranteed by BioLargo Inc. Each investor also received a warrant to purchase an aggregate number of Clyra common shares equal to the face amount of the note divided by 7.5, at an exercise price of $7.50 per share, expiring July 31, 2031. Warrants to purchase an aggregate 102,400 shares of Clyra common stock were issued to the investors.

 

Subsequent to September 30, 2026, Clyra sold SAFE instruments ("simple agreement for future equity") in the aggregate amount of $200,000 to one accredited investor. The SAFE instruments automatically convert into shares of the class or series of Clyra's common stock sold in a future qualifying equity financing (a bona fide capital raise at a fixed valuation with gross proceeds in excess of $7,500,000) at the lower of the price implied by a $100 million enterprise valuation and a 20% discount to the price sold in the qualifying equity financing.

 

Subsequent to September 30, 2026, Clyra entered into agreements extending the maturity dates of secured promissory notes in the aggregate principal amount of $1,260,000 to December 31, 2028 (see Note 8, Debt Obligations of Clyra Medical, Secured Promissory Notes). The notes continue to require monthly cash interest payments. In consideration for the extension, the expiration date of the warrants originally issued to the investors was extended by two years to December 31, 2031, and each investor received an additional warrant to purchase one-half the number of shares purchasable under their original warrant, at one cent per share, expiring December 31, 2031. Warrants to purchase an aggregate 136,585 shares of Clyra common stock were issued to the investors.

 

Executive Employment Agreement

 

On November 13, 2026, the Company and Joseph L. Provenzano entered into a five-year employment agreement whereby Mr. Provenzano will continue to serve as the Company's Vice-President of Operations, President/CEO of ONM Environmental, Inc., and President/CEO of BioLargo CPG LLC. Mr. Provenzano will continue to receive an annual base salary of $199,772.28. 

 

 

 

 

 

- 24 -

 

Item 2.              Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

This Quarterly Report on Form 10-Q contains forward-looking statements. These statements relate to future events or our future financial performance and include statements regarding our capital needs, business plans, liquidity and financial condition, availability of funds, operating costs, and the markets in which we compete. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," or "continue," or the negative of these terms or other comparable terminology. Any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. They are based on management’s current expectations and assumptions, and they are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Those risks and uncertainties include, among others, our history of net losses, our need for additional financing and possible limits on our access to capital markets; uncertainty about when we will become profitable; our reliance on third-party marketing partners, outside manufacturers and suppliers, and the absence of minimum purchase commitments from most customers; supply chain disruptions, tariffs and volatile raw material and ingredient costs; the risk that our technologies, including our liquid sodium battery, do not achieve market acceptance; difficulty managing growth; the cost and uncertainty of obtaining FDA, EPA, state and foreign regulatory approvals; the ineffectiveness of our disclosure controls and internal control over financial reporting; our dependence on key personnel; limits on our ability to protect our trade secrets and patents, and the risk that we infringe the intellectual property of others; product liability claims, litigation, regulatory actions and negative publicity; quarterly swings in our results, and seasonal and weather-related swings in sales; risks of international operations; intense competition from larger, better-funded companies; business disruptions, cybersecurity threats and data breaches; general economic and geopolitical conditions; and risks related to our common stock, including dilution from our equity line, stock-based payments, future financings and preferred stock, thin trading on the OTCQX, price volatility, penny stock rules and the absence of dividends. For a more complete discussion of these and other risks, see the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and our other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of this quarterly report. Except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Unless otherwise expressly stated herein, all statements, including forward-looking statements, set forth in this Form 10-Q are as of September 30, 2026, unless expressly stated otherwise, and we undertake no duty to update this information.

 

When we refer in this report to “BioLargo,” the “Company,” “our Company,” “we,” “us” and “our,” we mean BioLargo, Inc., and our subsidiaries, including BioLargo Life Technologies, Inc., which holds our intellectual property; ONM Environmental, Inc., which manufactures, markets, sells and distributes our odor and volatile organic compound ("VOC") control products; BioLargo Energy Technologies, Inc. (“BETI”), formed to commercialize our proprietary battery technology; BioLargo Canada, Inc., our primary research and development team operating in Edmonton, Alberta Canada; BioLargo Engineering, Science & Technologies, LLC (“BLEST”), a professional engineering services division in Oak Ridge Tennessee; BioLargo Equipment Solutions & Technologies, Inc., which sells our water treatment products; BioLargo CPG LLC ("BCPG"), which was formed in May 2026 to commercialize household consumer products based on our technologies; BioLargo Development Corp., which employs and provides benefits to our employees; and Clyra Medical Technologies, Inc. (“Clyra Medical”), which commercializes our technologies in the medical and dental fields. All subsidiaries are wholly owned, except for BETI, BLEST, BCPG and Clyra Medical.

 

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto included elsewhere in this report.

 

DESCRIPTION OF BUSINESS

 

Our Business - Innovator and Solution Provider

 

BioLargo is in the business of creating new cleantech technologies to solve tough, globally relevant problems. We invent, develop, then commercialize technologies that tackle difficult challenges in air quality, water, environmental engineering, battery energy storage, and advanced antimicrobial medical device platforms. Our model is to invent new technologies that solve specific problems, develop them and prove they work, and then commercialize them with purpose-suited subsidiaries, identify and secure the right partnerships to increase their commercial reach, or potentially sell the intellectual property.

 

Why do we do this work? Every member of our team – including PhD scientists, engineers, and entrepreneurs – has a passion for seeking new, never-before-seen innovations that can make life better around the world. We care about safeguarding the environment and human health for future generations. We care about making technologies that are affordable and flexible enough to be accessed around the world. And we care about doing the work well - developing technologies that solve meaningful cleantech challenges.

 

Some of our areas of focus include environmental problems like PFAS contamination, water pollution by pharmaceuticals and micropollutants, air pollution by VOCs, hard-to-treat odors from landfills and sewage plants, infection and wound healing and the creation of energy storage systems that are more affordable, efficient, safer and environmentally friendly.

 

Below you’ll read about the cleantech ventures and projects we are focused on commercialization today. Behind those, however, is a pipeline of other cleantech innovations in various stages of development associated with our expansive array of issued and pending patents, and that have been funded in part by over 90 government grants.

 

We operate our business in distinct business segments:

 

 

●

Odor and VOC control products, including consumer pet and household products under the "barebird" brand, and CupriDyne® Clean Industrial Odor Eliminator, sold by our subsidiary ONM Environmental, Inc.;

 

 

●

Water treatment equipment and solutions, including our PFAS remediation system the Aqueous Electrostatic Concentrator (AEC), our water reuse and recycling technology co-developed with Garratt-Callahan called AROS, and sold by our subsidiary BioLargo Equipment Solutions & Technologies, Inc.;

 

 

●

Battery energy storage systems designed for grid-scale energy storage and other industrial uses under the brand name Cellinity™ being developed by our partially owned (93%) subsidiary BioLargo Energy Technologies, Inc.;

 

 

●

Medical products based on our technologies sold by our partially owned (46%) subsidiary Clyra Medical Technologies, Inc.;

 

 

●

Our professional engineering services division, which, in addition to serving outside clients on a fee for service basis, supports our internal business units, through our partially owned (70%) subsidiary BioLargo Engineering, Science & Technologies, LLC ("BLEST");

 

 

●

Our research and support personnel, through our wholly-owned subsidiary BioLargo Canada, Inc., located on campus at the University of Alberta, Edmonton, Canada.

 

- 25 -

 

Odor Control (Consumer and Industrial)

 

ONM Environmental, Inc. ("ONM") is BioLargo’s wholly-owned subsidiary that delivers robust and comprehensive products and services to control and mitigate odor and VOCs for both consumer and industrial applications. Its flagship product – CupriDyne® Clean – is applied to odor-emitting masses such as landfills and composting facilities by misting systems, sprayers, water trucks and similar water delivery systems designed, manufactured and installed by ONM, is included in consumer products such as the "barebird" brand launched by the Company in October 2026, and sold to third parties under private label brands.

 

Consumer Products

 

In October 2026, we launched consumer odor-control products under our company-owned brand "barebird". The initial lineup includes two fragrance-free, 32-ounce products: barebird Pet Odor Eliminator for common household pet odors and barebird Laundry Odor Eliminator, a 16-load laundry additive designed to address persistent odors in clothing, towels and bedding. Both are sold directly to consumers, initially through the brand's e-commerce site, which launched on October 31, 2026. Management intends to expand ecommerce distribution to Amazon, social media and other selling channels. Additionally, ONM sells privately labeled odor-control products based on our technologies to third parties who market and sell the products under their own brand names.  

 

Industrial Odor and VOC Solutions

 

We believe CupriDyne Clean is the number-one performing industrial odor-control product in the market, and that it offers substantial savings to our customers compared with competing products. We have been and expect to continue selling product to municipalities and some of the largest solid waste handling companies in the country to help control odors emitted from waste handling and sanitation sites.  ONM Environmental offers a menu of services to landfills, transfer stations, wastewater treatment facilities as well as facilities in non-waste related industries. These services include engineering design, construction, installation, ongoing maintenance and on-site support services to assist our clients in the implementation and continued use of the various systems that deliver our liquid products in the field (such as misting systems). A significant portion of industrial odor control product and service revenue comes from ongoing contracts with cities and counties in Southern California, where ONM has installed comprehensive odor control systems to mitigate nuisance odors emitted from municipal waste handling and sanitation sites.

 

BioLargo Equipment Solutions & Technologies – Innovative Water Treatment Solutions

 

Over the years, we have developed multiple innovative technologies and equipment platforms that focus on challenging issues in the water treatment industry, including the AEC (developed to remove per- and polyfluoroalkyl substances, aka "PFAS"), and the AROS water reuse technology (for industrial cooling tower water recycling such as in data centers, co-developed with Garratt-Callahan). We sell these products through our wholly-owned subsidiary BioLargo Equipment Solutions & Technologies, Inc. (“BEST”), which manages the sales and distribution of our water treatment products and related services.  

 

BEST's board of directors includes Jeffrey Kightlinger, former CEO of the Metropolitan Water District of Southern California, Sally Gutierrez, retired career senior executive from the US Environmental Protection Agency (EPA), and Larry Dick, former Vice Chairman of the Metropolitan Water District of Southern California and board member of the Municipal Water District of Orange County. Each brings their significant and distinctive experience from decades in the water industry to BEST’s board to help the company create the necessary regulatory and industry connections that will be critical for its efforts to secure larger and more high-profile projects for its PFAS treatment and other water treatment technologies. These board members have been instrumental in efforts to raise awareness of our innovative treatment solutions within the water industry and EPA.  

 

Securing sales in the water and wastewater industry is a very technically intensive process and can be long and arduous. The entirety of the sales cycle can be lengthy, in some cases even taking many months or, in the case of very large projects, multiple years. A typical sales timeline for a municipal drinking water or wastewater customer, from introduction to signing the contract for a full-scale install, usually requires feasibility studies, on-site pilot projects, budget approvals, State regulatory approvals, and more. Industrial clients may have shorter sales cycles but are under pressure to ensure that the Return on Investment (ROI) fits into company standards, so their reviews can also be lengthy. For any water treatment project, the process is also very engineering-intensive, and therefore the staff required to secure contracts for water treatment projects need to be engineers, in most cases. In our company, BLEST’s engineers fill this role.

 

AEC, a solution for the PFAS “forever-chemicals” crisis

 

One of the most significant and timely innovations in our portfolio is our per- and polyfluoroalkyl substance (PFAS) water remediation system the Aqueous Electrostatic Concentrator (AEC), a novel water treatment system that removes PFAS from water at a lower operating cost while generating only a fraction of the PFAS-laden waste of the most common currently used solutions (carbon filtration, ion exchange, and reverse osmosis). PFAS are a group of man-made chemicals used for decades in the manufacture of both household and industrial goods, which have been detected in drinking water around the world. PFAS are a concern because they do not break down in the environment, can move through soil and contaminate drinking water sources, and build up (bioaccumulate) in fish, wildlife and humans. PFAS chemicals have been linked to cancer, immune disorders, liver dysfunction, and many other human health problems. Detection of unsafe levels of PFAS around the world has given rise to a number of market opportunities for treatment and remediation technologies, including in drinking water, industrial wastewater, municipal wastewater, solid waste, organic foods and more.

 

Our AEC unit has been up and running in Lake Stockholm, New Jersey, since January 2026, removing PFAS from drinking water for local residents. The AEC's performance is undergoing regular testing by both the U.S. EPA and the New Jersey Department of Environmental Protection to ensure it continues to meet their standards. We believe this project can validate for potential customers the AEC's use in municipal drinking water, and can showcase the AEC’s distinct advantages over incumbent technologies like carbon filtration and ion exchange, which include lower hazardous waste disposal costs. 

 

As a modular system, we believe the AEC is scalable to small commercial units used in smaller remediation projects for groundwater, wastewater, or landfill leachate, as well as large commercial installations of drinking water treatment facilities, and we believe that our engineering team has the experience to deliver systems to meet the needs of any sized commercial installation. In order to provide a full turn-key solution for our customers, we have developed an expanded offering whereby we can bundle a service package with each customer project that includes a membrane exchange program, the collection of PFAS, and transport and destruction of the PFAS using a novel “electrooxidation” process which our studies have shown is capable of reaching non-detect levels of PFAS after treating AEC-concentrated PFAS containing water, wastewater, or even landfill leachate (the contaminant-laden water that drains from landfills).

 

We have successfully validated the AEC as an effective system to selectively extract and collect PFAS chemicals from contaminated water, including performance testing that shows “non-detect” levels of removal, which meets both state and federal regulations. In addition to the use in Lake Stockholm New Jersey, we have demonstrated more than 10,000 hours of continuous operation showing no materially significant degradation of the AEC system’s components or performance over time, and believe the costs to operate our system will be far less than that of the two primary incumbent technologies.

 

 

- 26 -

 

As we progress through the commercial rollout of our AEC technology, we continue to invest in innovation aimed at enhancing its commercial viability. These efforts are focused on improving system performance, reducing lifecycle costs, and strengthening the AEC’s competitive position within the PFAS treatment market. We remain committed to delivering scalable, cost-effective solutions that align with evolving regulatory requirements and market demand. We believe we are well-positioned in the PFAS-removal market for multiple reasons. We have successfully completed over a dozen pilot studies with prospective customers’ PFAS contaminated water from a variety of source waters including groundwater, wastewater and leachate; we have successfully maintained operation of our AEC PFAS treatment system for over 10,000 hours continuously, thus demonstrating its resilience to long-term use; we have submitted bids and proposals and have received indications of interest from a wide range of customer types; we have added several high-profile experts from the industry to our team who are assisting in opening doors to potential clients and collaborators; we have entered into discussions about partnership and opportunities for collaboration with industry-leading firms who have a gap in their PFAS treatment technology portfolio. While these opportunities do not convert into commercial sales overnight, they represent strong avenues for accelerating adoption of our PFAS treatment solution.

 

AROS Minimal Liquid Discharge Water Treatment

 

In partnership with Garratt-Callahan, one of the country’s oldest and largest privately held water treatment companies, our engineers developed a “minimal liquid discharge” wastewater treatment system called the Aqueous Reuse Optimization System (AROS) that is designed to minimize industrial wastewater discharges and thus the associated regulatory fees. The system is particularly well-suited to reduce water usage at data centers and other high-water-use industrial facilities. Garratt-Callahan, who invented and patented the technology, is actively marketing the AROS system to its existing customer base and to new prospective customers, and we are supporting those efforts with commercial trials in our Oak Ridge facility.  

 

Advanced Oxidation System (AOS)

 

The Advanced Oxidation water treatment system (AOS) is our patented water treatment device that generates highly oxidative and energetic species of iodine and other molecules which allow it to eliminate pathogenic organisms and organic contaminants rapidly and effectively as water passes through the device. The key value proposition of the AOS is its ability to reduce or eliminate a wide variety of waterborne contaminants with high performance, including the normally hard-to-treat class of recalcitrant water contaminants called “micropollutants”, while using very little electricity and input chemicals. The AOS has been proven capable of removing hard-to-treat organic micropollutants such as pharmaceuticals from water more quickly and energy-efficiently than other technologies. While the AOS has demonstrated exceptional performance in both laboratory and pilot-scale testing, current U.S. regulatory frameworks have not yet matured to support broad adoption of advanced oxidation technologies for micropollutant removal. Additionally, the domestic market remains dominated by low-cost chemical disinfection solutions. We have turned our focus to Canada and have established a relationship with a local partner to develop commercial opportunities in the Canadian oil sands.

 

BioLargo Energy Technologies, Inc.

 

Our subsidiary BioLargo Energy Technologies, Inc. (“BETI”) was founded to commercialize a novel battery technology with the potential to help facilitate the ongoing shift toward renewable energy production by providing a safer, longer lasting, more eco-friendly, and more affordable alternative to lithium-ion batteries. Designed for long duration energy storage, also known as "battery energy storage systems" (BESS), our battery, called Cellinity™, uses a novel “liquid sodium” chemistry that uses common domestically sourced materials, and which has significant advantages over other battery chemistries for use in stationary, long-duration energy storage. 

 

BETI operates out of a pilot-scale battery production facility in our Oak Ridge Tennessee engineering headquarters, and is currently manufacturing and testing prototype battery cells. A third party has confirmed many of the technology's exceptional performance claims that we believe will make it an attractive battery technology for long duration energy storage and other industrial uses such as artificial intelligence data centers, electric vehicle charging stations, and renewable energy, including the stability of the chemistry of the battery cell and the reliability of the component construction as a sealed, non-venting cell design with no self-discharging, and the battery's ability to quickly charge and discharge at a high voltage. It has also been proven that the battery can withstand catastrophic physical insults without causing fire or explosion, one of the battery’s key features. With this data confirmed by a third party, our engineers have begun work advancing Cellinity's development, including the design of a larger sized battery cell that would then be incorporated into battery packs, modules and batteries meant for industrial facilities. Simultaneously, our engineers are working to develop manufacturing processes that would allow scale production and a supply chain necessary to ensure costs of goods in line with market demand and conditions. 

 

We believe our Cellinity batteries will have features that far surpass comparable lithium-ion batteries, the dominant incumbent technology in the market, including:

 

 

●

Increased safety, no runaway fire risks, and a more sustainable design – with no rare-earth elements – that is capable of being manufactured completely from a domestic supply chain;

 

●

Ability to charge and discharge completely, with no degradation of performance, ensuring virtually unlimited charge/discharge cycles, and without self-discharge and no out-gassing; and

 

●

Increased energy efficiency and energy density, and expected useful life expectancy of 20 years or more.

 

We are exploring multiple opportunities to commercialize our Cellinity batteries through joint ventures with third parties. The third parties would finance the construction of independent battery manufacturing facilities designed and built under the direction of our engineers, and the joint venture would market, manufacture and distribute batteries. BioLargo would (i) receive a minority equity position in each joint venture, (ii) separately manufacture and sell at a profit to the joint venture certain proprietary battery components, and (iii) receive a royalty on the revenues of the joint venture.

 

Given the global growing demand for better batteries, and, while we are witnessing a number of current examples in which battery manufacturers have secured forward-contracts to supply batteries to its customers with backlogs of orders that amount to multiple years of production capacity, we believe our offer to partner with customers to secure needed inventory provides for a clear potential pathway to access capital, and more readily scale up production to meet demand around the world. At this point, we do not intend to finance and build our own manufacturing facilities, nor would we develop in-house sales channels, although that possibility remains an option to explore if needed.

 

- 27 -

 

Clyra Medical Technologies, Inc.

 

Our partially owned subsidiary Clyra Medical Technologies, Inc. is a healthcare company that is developing and commercializing products based on our technologies designed to safely treat wound and skin infections and promote wound healing, while reducing the need for antibiotics. Clyra’s first products are based on its patented Clyrasept™ technology, which utilizes a Copper-Iodine Complex Solution (CICS) and received premarket clearance from the FDA under Section 510(k). Its first product is ViaCLYR®, a pH-balanced wound management solution indicated for wound management, cleansing, irrigation, moisturization, and debridement of acute and chronic wounds and burns, sold to U.S. healthcare providers through Advanced Solution, and federal healthcare customers through Spartan Medical. In May 2026 Clyra signed a distribution agreement with Al-Hikma FZCO, a healthcare distribution and marketing group headquartered in Dubai, United Arab Emirates, to exclusively distribute ViaCLYR across 18 countries spanning the Gulf Cooperation Council, the Levant, North Africa, and select adjacent markets. Al-Hikma is managing the regulatory process to obtain approval to sell ViaCLYR in the various jurisdictions. 

 

Over the past year, Clyra has made significant investments in personnel, processes, and skilled manufacturing capabilities while advancing product design, market testing, and clinical activities. The company has also expanded its outreach to clinicians and participation in industry meetings. These initiatives are designed to support existing distributors and position the company for the national rollout of an additional product line in collaboration with a confidential strategic partner. Thus far during fiscal year 2026, Clyra has raised $5,267,000, of which $5,067,000 are debt obligations guaranteed by BioLargo Inc., and $200,000 are SAFE instruments (see Note 8). 

 

Clyra has 12 full time employees, and has increased staff and raised capital to ready the company to launch additional products. Clyra’s management team includes Medical Director Dr. Jeffrey Marcus, formerlly the Chief of Plastic, Maxillofacial, and Oral Surgery at Duke University, Nicholas Valeriani, chairman of the board of directors of Edwards Lifesciences and who had a 34-year career with Johnson & Johnson where he held numerous leadership positions in engineering, manufacturing, sales and marketing, and Linda Park of Edwards Lifesciences, where she serves as Corporate Secretary, Senior Vice President and Associate General Counsel, and as a board member of the Edwards Lifesciences Foundation.

 

Full Service Environmental Engineering

 

BioLargo Engineering, Science & Technologies, LLC (“BLEST”) offers full service environmental engineering to third parties and provides engineering support services to our internal teams to accelerate the commercialization of our technologies. 

 

BLEST focuses its efforts in three areas:

 

 

●

providing engineering services to third-party clients as well as affiliated BioLargo entities;

 

●

supporting internal product development; and       

 

●

advancing their own technical innovations such as the AEC PFAS treatment technology and the Cellinity battery energy storage system.

 

BLEST operates out of an engineering facility in Oak Ridge, Tennessee (a suburb of Knoxville), and employs a group of scientists and engineers, many of whom are owners of the entity (BioLargo owns 70%). The team is led by Randall Moore, who served as Manager of Operations for Consulting and Engineering for the Knoxville office of CB&I Environmental & Infrastructure and was formerly a leader at The Shaw Group, Inc., a Fortune 500 global engineering firm. Many of the other team members are also former employees of CB&I and Shaw, with the exception of more recent staff hires. The team is highly experienced across multiple industries and we believe they are considered experts in their respective fields, including: chemical engineering, wastewater treatment (including design, operations, data gathering and data evaluation), process safety, energy efficiency, air pollution, design and control, technology evaluation, technology integration, air quality management and testing, engineering management, permitting, industrial hygiene, applied research and development, air testing, environmental permitting, HAZOP review, chemical processing, thermal design, computational fluid dynamics, mechanical engineering, mechanical design, NEPDES permitting, RCRA/TSCA compliance and permitting, project management, storm water design and permitting, computer assisted design (CAD), bench chemistry, continuous emission monitoring system operator, data handling and evaluation and decommissioning and decontamination of radiological and chemical contaminated facilities. The team has decades of high-level experience in the energy industry. The engineering team has also developed an extended network of trusted engineering subcontractors that assist in serving specific client projects as needed.

 

BLEST engineers generate revenue through services to third party clients, as well as for internal BioLargo projects such as the AEC and battery (revenues from internal projects are eliminated in the consolidation of our financial statements and are designated “intersegment revenue”). Third party contracts include ongoing work at U.S. Air Force bases for air quality control which generate ongoing contract-based revenue of approximately $100,000 per month. Efforts to expand this work as well as with other clients are consistently ongoing. In April 2026 BLEST was engaged to design a pilot-scale minerals processing facility that will remediate and, utilizing a patented BioLargo process, will create a beneficial reuse of a legacy mineral waste deposit associated with a historically impacted site in the western United States. Work on the $1.2 million contract has begun and is expected to continue through second quarter of 2027, and is expected to lead to the design and construction of a larger processing facility. 

 

The staff time devoted to supporting the AEC (PFAS) and battery related work is demanding, and BLEST needs to hire more qualified staff to meet an expanding demand for our growing list of customers. When we combine the demands of current revenue generating projects and expected growth, we are presented with an obvious challenge to manage quality, timely performance as well as access to qualified staff. We are working carefully to find balance to help ensure we meet the demands of both in a practical customer centric and capital conserving way. It may be, for example, that we will eventually need to secure contract manufacturers to meet the customer demands in the near term as we scale up our infrastructure and work force capabilities.

 

- 28 -

 

RESULTS OF OPERATIONS

 

Our net loss for the three and nine months ended September 30, 2026 was $3,824,000 and $11,229,000, and mainly reflects spending to commercialize our technologies, particularly at Clyra Medical. Clyra accounted for $2,147,000 and $6,421,000 of the net loss for the three and nine month periods, about 56% and 57% of the consolidated net loss. During these periods, Clyra invested in personnel, manufacturing capabilities, product development and clinical activities to support its distributors and to prepare for the national rollout of an additional product line. Clyra financed this work largely through debt, which also increased our interest expense. We also continued to invest in other business segments and technologies, including our Cellinity battery, AEC PFAS treatment system, and the launch of the "barebird" consumer odor control products. As a result, consolidated research and development expense increased 32% and 45%, and SG&A increased 5% and 12%, compared with the same periods in 2025. Excluding the $3,849,000 credit loss expense recorded in the third quarter of 2025, our net loss increased by $429,000 and $4,031,000 in the three and nine month periods, mostly because of higher costs at Clyra Medical. Revenues decreased 1% and 52% in the three and nine month periods. This decline came mainly from lower sales of private-labeled pet odor control products and was partially offset by higher engineering service revenue. 

 

ONM Environmental

 

Our wholly-owned subsidiary ONM Environmental generates revenues through sales of our flagship product CupriDyne Clean to industry, including related design, installation, and maintenance services on the systems that deliver CupriDyne Clean at its clients’ facilities, and to consumers, through its consumer brand "barebird" and under private label to third parties. ONM Environmental’s revenues decreased  33% and 75% in the three and nine months ended September 30, 2026, compared with the same periods in 2025. The decrease in revenues was due to a decrease in the volume of sales of pet odor products private labeled to a third party under the brand name "Pooph", offset by an increase in the volume of sales of industrial odor control products. The company brand "barebird" products were first sold after the end of the third quarter. 

 

ONM Environmental’s cost of goods sold includes costs of raw materials, contract manufacturing, and portions of depreciation, salaries and expenses related to the manufacturing and installation of its products. As a percentage of revenue, ONM Environmental’s costs of goods sold for the three and nine months ended September 30, 2026, were 29% and 33%, a decrease of 25% and 17% compared to the same periods in 2025. The decrease in cost of goods sold is due to the change to more commercial sales versus retail sales, which have lower product costs.

 

ONM Environmental’s selling, general and administrative expenses ("SG&A") for the three and nine months ended September 30, 2026 totaled $416,000 and $1,186,000, an increase of 33% and 28% compared with the same periods in 2025. The increase is due to increases in expenses related to the Pooph litigation, salaries, professional fees and insurance expense.

 

ONM Environmental generated an operating loss totaling $45,000 and $241,000 in the three and nine months ended September 30, 2026, compared to an operating loss totaling $3,807,000 and $2,026,000 for the three and nine months ended September 30, 2025. The operating loss is primarily due to the decrease in revenues in the comparable periods.

 

BLEST (engineering)

 

BLEST generated $563,000 and $1,879,000 in third-party service revenues in the three and nine months ended September 30, 2026, an increase of 72% and 20% compared to the third-party service revenues in the same periods in 2025. This increase was due to an increase in fixed fee contracts at U.S. Air Force bases and an environmental remediation project. In addition to providing services to third party clients, BLEST provides services for internal BioLargo projects. These services are billed internally, are considered intersegment revenue, and are eliminated in the consolidation of our financial statements. In the three and nine months ended September 30, 2026, intersegment revenue for BLEST totaled $226,000 and $800,000.  In the three and nine months ended September 30, 2025, intersegment revenue for BLEST totaled $123,000 and $515,000.

 

BLEST’s cost of revenues includes employee labor, subcontracted costs and material costs. In the three and nine months ended September 30, 2026, costs were 74% and 67% of revenues, versus 96% and 66%, respectively, in the same periods in 2025. The reduction in the three months ended September 30, 2026 is related to engineering service contracts with higher margins. For the nine months ended September 30, 2026 compared with 2025, the margin was essentially the same.

 

 

BLEST’s SG&A expenses were $

220,000

 and $

649,000

in the

three and nine months ended September 30, 2026

, compared to $

198,000

 and $

752,000

in the

three and nine months ended September 30, 2025

. The increase for the three months is due to a new employee, insurance and rent and the decrease for the nine months is due to the timing of expenses in the prior period and does not reflect an increase in SG&A activity or employees.  

 

 

BLEST generated an operating loss of $306,000 and $727,000 in the three and nine months ended September 30, 2026, compared to an operating loss of $403,000 and $763,000 in the three and nine months ended September 30, 2025.  The operating losses are reflective of the focus at BLEST on advancing internal BioLargo projects such as the Cellinity battery and AEC water treatment system. 

 

 

- 29 -

 

Clyra Medical

 

As Clyra completes its transition from product development to commercialization, with ViaCLYR now available through U.S. distributors, a new international distribution agreement covering 18 countries, and a growing team preparing for additional product launches, its results for 2026 reflect an early-stage revenue base alongside deliberate investment in people, manufacturing, and clinical activities. It did not generate revenue in the three months ended September 30, 2026, and generated revenues of $154,000 in the nine months ended September 30, 2026 from the sale of ViaCLYR wound irrigation solution.  Clyra Medical did not generate revenue in 2025. In the three and nine months ended September 30, 2026, Clyra incurred an operating loss of $1,843,000 and $5,669,000, which included $432,000 and $1,563,000 in research and development expenses. In the same periods in 2025, the operating loss totaled $1,483,000 and $4,063,000, which included $231,000 and $795,000 in research and development expenses. The increases in costs and expenses are primarily related to an increased number of employees, increased product development work, and stock option expense.  

 

BETI

 

BioLargo Energy Technologies, Inc. (BETI) is developing our Cellinity battery, and has not generated revenue. For the three and nine months ended September 30, 2026, it incurred total costs and expenses of $332,000 and $1,026,000, which included $146,000 and $444,000 in research and development expenses.  In the same periods in 2025, total costs and expenses were $128,000 and $346,000, which included $47,000 and $161,000 in research and development expenses.  The increase in expenses is due to preparing for commercialization of the product and in finding financial partners.

 

BEST

 

BioLargo Equipment Solutions & Technologies, Inc. (BEST) sells BioLargo's proprietary water treatment equipment, including its PFAS removal device the AEC. As the first AEC sale occurred prior to the Company's formation, and the sales cycle for advanced water treatment systems is long, BEST has not yet generated revenues. During the three and nine months ended September 30, 2026, it incurred $87,000 and $252,000 of total expenses. In the same periods in 2025, it incurred $83,000 and $208,000 in total expenses primarily related to administrative activities.

 

Selling, General and Administrative Expense – consolidated

 

Our SG&A expenses include both cash and non-cash expenses (for example, stock option compensation expense). For the three and nine months ended September 30, 2026 consolidated SG&A increased 5% and 12% as compared with the three and nine months ended September 30, 2025. The largest components of our SG&A expenses included (in thousands):

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30, 2026

   

September 30, 2025

   

September 30, 2026

   

September 30, 2025

 

Salaries and payroll related

  $ 1,050     $ 1,376     $ 2,956     $ 3,575  

Professional fees

    380       131       1,305       616  

Consulting

    435       586       1,304       1,342  

Office expense

    561       524       1,823       1,428  

Rent expense

    136       104       428       350  

Depreciation expense

    128       33       192       109  

Sales and marketing

    295       136       516       400  

Investor relations

    114       135       387       280  

Board of director expense

    129       63       387       239  

Total Selling, General & Administrative

  $ 3,228     $ 3,088     $ 9,298     $ 8,339  

 

In the three and nine months ended September 30, 2026, our non-cash expenses from the issuance of stock and stock options totaled $1,049,000 and $2,793,000 compared to $899,000 and $2,339,000 for the three and nine months ended September 30, 2025. The majority of this stock option expense is recorded in employee salaries and consulting expense. The reduction in salaries and payroll related expenses is due to an Employee Retention Tax Credit recognized in the nine months ended September 30, 2026, offset by an increased number of employees. Professional fees increased in the three and nine months ended September 30, 2026, due to increased corporate activity related to new private securities offerings for BioLargo and Clyra, legal proceedings related to ONM Environmental, and other organizational needs that required professionals. Office expense increased due to an increase in insurance premiums.  

 

Research and Development

 

In the three and nine months ended September 30, 2026, we recorded $810,000 and $2,805,000 in the research and development of our technologies and products. This was an increase of 32% and 45% as compared to the three and nine months ended September 30, 2025.  The increase is primarily due to the continued development of Clyra’s medical products and manufacturing capabilities, and the Cellinity battery technology.

 

Interest Income and Expense

 

Our interest income for the three and nine months ended September 30, 2026, was $15,000 and $100,000 compared to $80,000 and $143,000 in the three and nine months ended September 30, 2025. Our interest expense for the three and nine months ended September 30, 2026, was $317,000 and $790,000 compared to $144,000 and $352,000 in the three and nine months ended September 30, 2025. The increase is related to the increase of Clyra Medical debt obligations. 

 

Other Income and Expense

 

For the three and nine months ended September 30, 2026, we did not receive any grant income, compared to no grant income for the three months ended September 30, 2025, and $6,000 of grant income for the nine months ended September 30, 2025. Grant income is primarily generated through our wholly owned Canadian subsidiary. The research grants received are considered reimbursement grants related to costs we incur and therefore are included as Other Income. Grant funds paid directly to third parties are not included as income in our condensed consolidated financial statements.

 

- 30 -

 

Net Loss

 

Net loss for the three and nine months ended September 30, 2026, was $3,824,000 and $11,229,000 a loss of $ (0.01) and $ (0.02) per share, compared to a net loss for the three and nine months ended September 30, 2025, of $7,244,000 and $11,047,000, a loss of $ (0.02) and $ (0.03) per share. A credit loss expense of $3,849,000 was recorded in the three months ended September 30, 2025, and increased the net loss for the three and nine months ended September 30, 2025. No credit loss expense was recorded in the three and nine months ended September 30, 2026. Without the credit loss expense, net loss for the three months ended September 30, 2026 increased by $429,000 as compared with the same period in 2025. The increase was due to an increase in SG&A, research and development, and interest expenses, primarily related to Clyra Medical's operations. Without the credit loss expense, net loss for the nine months ended September 30, 2026 increased by $4,031,000 as compared with the same period in 2025. The increase was due to an increase in SG&A, research and development, and interest expenses, primarily related to Clyra Medical's operations, and a decrease in gross profit.

 

The net income (loss) per business segment is as follows (in thousands):

 

   

Three Months Ended

   

Nine Months Ended

 
   

September 30, 2026

   

September 30, 2025

   

September 30, 2026

   

September 30, 2025

 

BioLargo corporate

  $ (847 )   $ (1,169 )   $ (2,220 )   $ (3,025 )

ONM

    (44 )     (3,764 )     (243 )     (1,936 )

Clyra Medical

    (2,147 )     (1,608 )     (6,421 )     (4,385 )

BLEST

    (306 )     (388 )     (727 )     (748 )

BETI

    (332 )     (128 )     (1,026 )     (346 )

BEST

    (87 )     (83 )     (252 )     (208 )

BCPG

    (34 )     —       (94 )     —  

BioLargo Canada

    (27 )     (104 )     (246 )     (399 )

Net loss

  $ (3,824 )     (7,244 )     (11,229 )     (11,047 )

 

Liquidity and Capital Resources

 

For the nine months ended September 30, 2026, we generated revenues of $3,452,000, had a net loss of $11,229,000, used $8,182,000 net cash in operating activities, and received $6,075,000 net cash from financing activities, of which 77% was received through subsidiary financings. As of September 30, 2026, we had current assets of $3,545,000, including $1,533,000 cash and cash equivalents. As of September 30, 2026, we had current liabilities of $5,936,000, and working capital deficit of $2,391,000. Given the history of the Company's recurring losses, negative cash flow, and uncertainty related to operational revenues and gross profits in future periods, it is unknown whether gross profits in the next twelve months will be sufficient to fund our operational costs, and therefore expect we will continue to need further investment capital to fund our business plans and investments in our technologies. The foregoing factors raise substantial doubt about our ability to continue as a going concern, unless we are able to increase revenues, generate gross profits from operations, and/or generate cash from financing activities. If we are unable to raise additional cash through gross profits or financing activities, management may choose to curtail portions of our operations. The condensed consolidated financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern.

 

Critical Accounting Policies

 

Our discussion and analysis of our results of operations and liquidity and capital resources are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of our condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, valuation of offerings of debt with equity or derivative features which include the valuation of the warrant component, any beneficial conversion feature and potential derivative treatment, and share-based payments. We base our estimates on anticipated results and trends and on various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. By their nature, estimates are subject to an inherent degree of uncertainty. Actual results that differ from our estimates could have a significant adverse effect on our operating results and financial position.

 

Our significant accounting policies and methods used in the preparation of the Company’s condensed consolidated financial statements are described in (i) in Part I, Item 1 of this Form 10-Q, Note 2, “Summary of Significant Accounting Policies” and (ii) in the Form 10-K for the year ended December 31, 2025, filed with the SEC on March 4, 2026, in the Notes to Consolidated Financial Statements in Part II, Item 8, and “Critical Accounting Policies and Estimates” in Part II, Item 7. There have been no material changes to the Company’s critical accounting policies and estimates since the filing of its Form 10-K.

 

- 31 -

 

Item 4.         Controls and Procedures

 

We conducted an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended – the “Exchange Act”) as of the end of the period covered by this Report. There were no changes in our internal control over financial reporting during the quarter ended September 30, 2026, which were identified in connection with management’s evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Exchange Act, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

 

Our procedures have been designed to ensure that the information relating to our company, including our consolidated subsidiaries, required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. However, our Company is continuing to grow and evolve as we diversify our product offerings and types of clients, increasing strain on our accounting systems. These activities put stress on our overall controls and procedures. We do not yet have the resources to implement the more sophisticated control systems used by larger companies. Although we have made some improvements, our chief executive officer and chief financial officer have concluded that, as of the evaluation date, our disclosure controls and procedures were not effective, due to the material weakness identified below.

 

It should be noted that the design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, regardless of how remote.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements. 

 

Under the supervision and with the participation of our management, including our chief executive officer and the chief financial officer, we have established internal control procedures in accordance with the guidelines established in the 2013 Framework —Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Management evaluated the effectiveness of our internal controls, and concluded that due to our limited financial and personnel resources, the fact that we operate our business in four distinct locations in the U.S. and Canada, and the lack of sophisticated reporting systems, we continue to have a material weakness in our internal controls with respect to the closing of our financial statements. Until the Company has the financial resources to implement more robust automated systems, or to hire additional dedicated accounting personnel, we expect this material weakness to continue.

 

Our management, including our chief executive officer and chief financial officer, does not expect that our disclosure controls or our internal control over financial reporting, or any system we design or implement in the future, will prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

- 32 -

 

PART II

 

OTHER INFORMATION

 

Item 1.          Legal Proceedings

 

ONM Environmental, Inc. is the defendant in a lawsuit filed by Pooph Inc. in the Orange County, California Superior Court on September 11, 2025. The lawsuit alleges three causes of action, for Breach of Contract, Breach of Implied Covenant of Good Faith and Fair Dealing, and Declaratory judgment, and seeks an unspecified amount of damages, allegedly arising from ONM’s manufacture of pet odor-control products sold by Pooph Inc. BioLargo, Inc., BioLargo Life Technologies, Inc. and ONM Environmental, Inc. filed a lawsuit against Pooph, Inc. and Ikigai Marketing Works, LLC in the United States District Court, Central District of California, on November 11, 2025, for patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices and constructive fraud, seeking to recover, amongst other damages, the defendants’ failure to pay for product purchases and license royalties in the aggregate amount of $3,821,401. See Note 2, Allowance for Credit Losses, in Part I above.

 

Item 2.          Unregistered Sales of Equity Securities and Use of Proceeds

 

On September 30, 2026, we issued 1,807,444 shares of our common stock at $0.08 per share in lieu of $154,000 of accrued and unpaid obligations to two officers. On September 30, 2026, we issued 705,000 shares of our common stock at $0.08 per share in lieu of $61,000 of accrued and unpaid obligations to consultants and vendors. 

 

All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933 and/or Regulation D promulgated thereunder as not involving a public offering of securities

 

Item 5.          Other Information

 

Clearthink Financing

 

On March 20, 2026, we entered into a purchase agreement (the “Purchase Agreement”) with Clearthink Capital Partners, LLC (“Clearthink”), pursuant to which Clearthink has committed to purchase up to $10.0 million of our common stock, par value $0.00067 per share (the “Common Stock”), subject to certain limitations and the satisfaction of the conditions set forth in the Purchase Agreement. On April 9, 2026, we filed with the SEC a registration statement on Form S-1 registering Clearthink's sale of the shares to be issued to Clearthink under the Purchase Agreement, which was declared effective by the SEC on April 15, 2026. From the April 15, 2026 commencement date through September 30, 2026, we sold 10,350,000 shares of our common stock to Clearthink and received $1,103,000 in gross and net proceeds. 

 

Executive Employment Agreement

 

On November 13, 2026, the Company and its subsidiary, BioLargo Development Corp., entered into an Employment Agreement with Joseph L. Provenzano. Under the agreement, Mr. Provenzano serves as Corporate Secretary and Vice President of Operations, and as President and Chief Executive Officer of ONM Environmental, Inc. and BioLargo CPG LLC. The agreement replaces his employment agreement dated May 28, 2019. It has an initial five-year term and renews automatically for one-year periods unless either party gives 90 days' notice of non-renewal.

 

Mr. Provenzano receives an annual base salary of $199,772.28, which may not be reduced without his consent. He is eligible for bonuses and stock option awards at the discretion of the Compensation Committee. He also receives health insurance premiums for himself and his family, life and disability insurance, and other benefits available to senior employees generally. In addition, the Company pays the costs of an industrial truck that Mr. Provenzano owns and uses in the Company's business. The agreement confirms that Mr. Provenzano was previously granted 500,000 Series C membership interests in BioLargo CPG LLC, which are fully vested. The agreement grants no additional equity.

 

The agreement provides for severance if the Company terminates Mr. Provenzano's employment without cause, if he resigns for good reason, or if the Company terminates his employment in connection with a merger, acquisition, bankruptcy or dissolution of the Company. In each case, he would receive accrued compensation plus a lump-sum severance payment, paid within 30 days. The payment equals one year's compensation plus the greater of (a) one-half year's compensation for each year of service after November 13, 2026, or (b) one-half year's compensation for each year remaining in the term. A partial year of service counts as a full year. For this purpose, one year's compensation is his highest annual base salary plus the greater of his most recent annual bonus or his average annual bonus for the prior three fiscal years. The severance obligation ends if, while severance is payable, he dies or an event occurs that would have permitted termination for cause or disability. If his employment ends for any other reason, he receives only accrued compensation.

 

If any payment under the agreement is subject to the golden parachute excise tax, the Company will pay Mr. Provenzano a gross-up so that his net benefit is the same as if the excise tax did not apply. Mr. Provenzano is bound by a perpetual confidentiality obligation and by an invention assignment. He has also agreed not to compete with the Company while employed and not to solicit Company employees or consultants for two years after his employment ends.

 

This summary is qualified in its entirety by the Employment Agreement, which is filed as Exhibit 10.15 to the Company's Quarterly Report on Form 10-Q filed November 16, 2026.

 

- 33 -

 
 

Item 6.         Exhibits

 

See the Exhibit Index for a list of exhibits filed as part of this report and incorporated herein by reference.

 

Exhibit Index

 

   

Exhibit

Number

Exhibit Description

3.1

Amended and Restated Bylaws (incorporated by reference to Exhibit 3.5 to the Company's annual report on Form 10-KSB filed on May 23, 2003)

3.2

Amended and Restated Certificate of Incorporation for BioLargo, Inc. filed March 16, 2007 (incorporated by reference to Exhibit 3.1 to the Company's annual report on Form 10-KSB filed on May 4, 2007)

3.3

Certificate of Amendment to Certificate of Incorporation, filed May 25, 2018 (incorporated by reference to Exhibit 3.4 to the Company's Post Effective Amendment on Form Pos Am filed on June 22, 2018)

3.4

Certificate of Amendment to Certificate of Incorporation, filed August 30, 2022 (incorporated by reference to Exhibit 3.4 to the Company's quarterly report on Form 10-Q filed on November 14, 2022)

4.1

Form of Stock Options issued in exchange for reduction in accounts payable. (incorporated by reference to Exhibit 4.12 to the Company's annual report on Form 10-K filed on March 31, 2015)

4.2

2018 Equity Incentive Plan (incorporated by reference to Exhibit 4.1 to the Form S-8 filed on June 22, 2018)

4.3

2024 Equity Incentive Plan (incorporated by reference to Exhibit 4.3 to the Company's quarterly report on Form 10-Q filed on May 15, 2026)

4.4

Revolving Line of Credit Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay (incorporated by reference to Exhibit 10.6 to the Company's current report on Form 8-K filed on July 7, 2020)

4.5

Security Agreement dated June 30, 2020, between Clyra Medical and Vernal Bay (incorporated by reference to Exhibit 10.7 to the Company's current report on Form 8-K filed on July 7, 2020)

4.6

Revolving Line of Credit Note issued by Clyra Medical to Vernal Bay on June 30, 2020 (incorporated by reference to Exhibit 10.8 to the Company's current report on Form 8-K filed on July 7, 2020)

4.7

Warrant issued in BioLargo Unit Offerings (through January 16, 2024) (incorporated by reference to Exhibit 4.22 to the Company's quarterly report on Form 10-Q filed on August 14, 2020)

4.8 Registration Rights Agreement between BioLargo Inc. and Clearthink Capital Partners LLC dated March 20, 2026 (incorporated by reference to Exhibit 4.1 to the Company's current report on Form 8-K filed on March 25, 2026)
10.1 BioLargo license to Clyra Medical Technologies, Inc., dated March 1, 2024 (incorporated by reference to Exhibit 10.1 to the Company's annual report on Form 10-K filed on April 1, 2024)
10.2 Clyra Medical Technologies, Inc. license to BioLargo dated March 1, 2024 (incorporated by reference to Exhibit 10.2 to the Company's annual report on Form 10-K filed on April 1, 2024)

10.3

Form of indemnity agreement between the Company and its officers and directors (incorporated by reference to Exhibit 10.23 to the Company's annual report on Form 10-K filed on March 31, 2023)

10.4

Commercial Office Lease Agreement for 14921 Chestnut St., Westminster, CA 92683 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on August 24, 2016)

10.5†

Employment Agreement with Dennis P. Calvert dated May 2, 2017. (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on May 4, 2017)

10.6

Commercial Office Lease Agreement for Oak Ridge Tennessee (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on September 8, 2017)

10.7†

Employment Agreement with Joseph L. Provenzano dated May 28, 2019 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on June 24, 2019)

10.8

Form of Share Exchange Agreement between BioLargo, Inc., and purchasers of Clyra Medical Series A Preferred Stock (incorporated by reference to Exhibit 10.20 to the Company's quarterly report on Form 10-Q filed on May 17, 2023)

10.9

Form of Share Exchange Agreement between BioLargo, Inc., and purchasers of BioLargo Energy Technologies, Inc. common stock (incorporated by reference to Exhibit 10.21 to the Company's quarterly report on Form 10-Q filed on May 17, 2023)

10.10 License Agreement between BioLargo, Inc., and Ikigai Holdings, LLC, dated May 17, 2021 (incorporated by reference to Exhibit 10.17 to the Company's quarterly report on Form 10-Q filed on August 14, 2025)
10.11 First amendment to License Agreement between BioLargo, Inc., and Ikigai Holdings, LLC, dated August 16, 2021 (incorporated by reference to Exhibit 10.18 to the Company's quarterly report on Form 10-Q filed on August 14, 2025)

 

- 34 -

 

10.12 Preferred Master Manufacturing Agreement between ONM Environmental, Inc., and Ikigai Holdings, LLC, dated July 9, 2021 (incorporated by reference to Exhibit 10.19 to the Company's quarterly report on Form 10-Q filed on August 14, 2025)
10.13 First amendment to Preferred Master Manufacturing Agreement between ONM Environmental, Inc., and Ikigai Holdings, LLC, dated June 6, 2025 (incorporated by reference to Exhibit 10.20 to the Company's quarterly report on Form 10-Q filed on August 14, 2025)
10.14 Purchase Agreement between BioLargo Inc. and Clearthink Capital Partners LLC dated March 20, 2026 (incorporated by reference to Exhibit 10.1 to the Company's current report on Form 8-K filed on March 25, 2026)
10.15* Employment Agreement bewteen the Company and Joseph L. Provenzano dated November 13, 2026.

31.1*

Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and 15(d)-14 under the Securities Exchange Act of 1934

31.2*

Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and Rules 13(a)-14 and 15(d)-14 under the Securities Exchange Act of 1934 

32*

Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 

101.INS**

Inline XBRL Instance

101.SCH**

Inline XBRL Taxonomy Extension Schema

101.CAL**

Inline XBRL Taxonomy Extension Calculation

101.DEF**

Inline XBRL Taxonomy Extension Definition

101.LAB**

Inline XBRL Taxonomy Extension Labels

101.PRE**

Inline XBRL Taxonomy Extension Presentation

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101)

 

* Filed herewith

** Furnished herewith

† Management contract or compensatory plan, contract or arrangement

 

- 35 -

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: November 16, 2026

 

BIOLARGO, INC.

 

 

By: /s/ DENNIS P. CALVERT

   

Dennis P. Calvert

Chief Executive Officer

     
     
Date: November 16, 2026  

By: /s/ CHARLES K. DARGAN, II

   

Chief Financial Officer

 

- 36 -

Keep reading